Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.7.11.30 - receptor protein serine/threonine kinase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Spontaneous
[Study on the correlation of transforming growth factor beta1 and its receptors with spontaneous abortion after in vitro fertilization and embryo transfer]
Abruptio Placentae
BMPR2 is required for postimplantation uterine function and pregnancy maintenance.
Abscess
Expression of various TGF-beta isoforms and type I receptor in necrotizing human brain lesions.
Acidosis
Disruption of auto-inhibition underlies conformational signaling of ASIC1a to induce neuronal necroptosis.
Acrospiroma
Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma.
ACTH-Secreting Pituitary Adenoma
Bone morphogenetic protein 4 and bone morphogenetic protein receptor expression in the pituitary gland of adult dogs in healthy condition and with ACTH-secreting pituitary adenoma.
Acute Kidney Injury
Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis.
Necroptosis in 3-chloro-1, 2-propanediol (3-MCPD)-dipalmitate-induced acute kidney injury in vivo and its repression by miR-223-3p.
Novel Roles of Necroptosis Mediator Receptor-Interacting Protein Kinase 3 in Kidney Injury.
RIPK3 mediates renal tubular epithelial cell apoptosis in endotoxin?induced acute kidney injury.
RIPK3 promotes sepsis-induced acute kidney injury via mitochondrial dysfunction.
The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases.
Acute Lung Injury
RIPK3 mediates pathogenesis of experimental ventilator-induced lung injury.
Adenocarcinoma
Activin-like kinase 5 (ALK5) inactivation in the mouse uterus results in metastatic endometrial carcinoma.
Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer.
Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment.
Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling.
Inhibition of bone morphogenetic protein receptor 2 suppresses pancreatic ductal adenocarcinoma growth by regulating GRB2/PI3K/AKT axis.
Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis.
Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES.
Overexpression of c-Met/hepatocyte growth factor receptors in human prostatic adenocarcinoma.
Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage.
Receptor-interacting protein kinase 3 as a predictive adjuvant chemotherapy marker after lung adenocarcinoma resection.
RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1? release, and efficient paracrine dendritic cell activation.
Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study.
The role of Sp1 in the differential expression of transforming growth factor-beta receptor type II in human breast adenocarcinoma MCF-7 cells.
The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma.
Adenocarcinoma of Lung
Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src.
lncCRLA enhanced chemoresistance in lung adenocarcinoma that underwent epithelial-mesenchymal transition.
Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness.
Mutations and reduced expression of the transforming growth factor-beta receptor II gene in rat lung adenocarcinomas induced by N-nitrosobis-(2-hydroxypropyl)amine.
Receptor-interacting protein kinase 3 as a predictive adjuvant chemotherapy marker after lung adenocarcinoma resection.
Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells.
Adenocarcinoma, Bronchiolo-Alveolar
Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES.
[Distribution of transforming growth factor-beta and its receptor in bronchiolo-alveolar cell hyperplasia and bronchiolo-alveolar carcinoma]
Adenoma
Acceleration of c-myc-induced hepatocarcinogenesis by Co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1 signaling disruption.
Down-regulation of TGF-beta receptors in human colorectal cancer: implications for cancer development.
Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
Expression of bone morphogenetic protein-6 and bone morphogenetic protein receptors in myoepithelial cells of canine mammary gland tumors.
Functional roles of the bone morphogenetic protein system in thyrotropin signaling in porcine thyroid cells.
Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.
Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis.
Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling.
The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer.
Transforming growth factor-beta receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas.
Transforming growth factor-beta type II receptors and smad proteins in follicular thyroid tumors.
[Changes in gene expression during the proliferative processes of parathyroid gland]
Adrenocortical Carcinoma
Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
Alzheimer Disease
Expression of Ripk1 and DAM genes correlates with severity and progression of Krabbe disease.
Immunohistochemical Analysis of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) Expression in the Rat and Human Hippocampus: Decline in CA3 During Progression of Alzheimer's Disease.
Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment.
RIPK1 mediates a disease-associated microglial response in Alzheimer's disease.
RIPK1 promotes inflammation and ?-amyloid accumulation in Alzheimer's disease.
The Expression of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) in Hippocampal Arterioles Declines During Progression of Alzheimer's Disease.
Ameloblastoma
Immunoexpression of BMP-2 and BMP-4 and their receptors, BMPR-IA and BMPR-II, in ameloblastomas and adenomatoid odontogenic tumors.
Amyotrophic Lateral Sclerosis
Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation.
Anemia
Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry.
Deficiency of the BMP Type I receptor ALK3 partly protects mice from anemia of inflammation.
Endothelial depletion of Acvrl1 in mice leads to arteriovenous malformations associated with reduced endoglin expression.
Aneurysm
Aneurysm syndromes and TGF-beta receptor mutations.
Aneurysm syndromes caused by mutations in the TGF-beta receptor.
Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system.
Prevalence of and Factors Associated with Arterial Aneurysms in Patients with Hereditary Hemorrhagic Telangiectasia: 17-year Retrospective Series of 418 Patients.
Transforming Growth Factor-beta Signaling in Thoracic Aortic Aneurysm Development: A Paradox in Pathogenesis.
Aneurysm, Dissecting
Transforming growth factor-beta receptor type II mutation in a patient with bicuspid aortic valve disease and intraoperative aortic dissection.
[Familial aortic dissection of non-Marfan syndrome with mutations in the transforming growth factor-beta receptor type 1 genes].
Angiodysplasia
Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1.
DHPLC-based mutation analysis of ENG and ALK-1 genes in HHT Italian population.
[Analysis of molecular background of hereditary haemorrhagic telangiectasia--Rendu-Osler-Weber disease--preliminary results]
Anovulation
Alteration of TGFB1, GDF9, and BMPR2 gene expression in preantral follicles of an estradiol valerate-induced polycystic ovary mouse model can lead to anovulation, polycystic morphology, obesity, and absence of hyperandrogenism.
Aortic Aneurysm
[Marfan-like aortic aneurysm syndrome; A surgical experience with Loeys-Dietz syndrome]
Aortic Aneurysm, Abdominal
Association of the TGF-beta receptor genes with abdominal aortic aneurysm.
Aortic Aneurysm, Thoracic
Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation.
Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections.
Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity.
Aortic Valve Disease
AGEs-RAGE axis causes endothelial-to-mesenchymal transition in early calcific aortic valve disease via TGF-?1 and BMPR2 signaling.
Arteriovenous Malformations
Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs.
Altered endothelial gene expression associated with hereditary haemorrhagic telangiectasia.
Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system.
Association of ACVRL1 genetic polymorphisms with arteriovenous malformations: A case-control study and meta-analysis.
BMPR2 gene mutation in pulmonary arteriovenous malformation and pulmonary hypertension: a case report.
Characterization of pulmonary arteriovenous malformations in ACVRL1 versus ENG mutation carriers in hereditary hemorrhagic telangiectasia.
Conditional knockout of activin like kinase-1 (ALK-1) leads to heart failure without maladaptive remodeling.
Context-specific interactions between Notch and ALK1 cannot explain ALK1-associated arteriovenous malformations.
Contribution of oxidative stress to endothelial dysfunction in hereditary hemorrhagic telangiectasia.
Cost comparison of genetic and clinical screening in families with hereditary hemorrhagic telangiectasia.
Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry.
De novo cerebrovascular malformation in the adult mouse after endothelial Alk1 deletion and angiogenic stimulation.
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients.
Effect of Transcriptional Regulator ID3 on Pulmonary Arterial Hypertension and Hereditary Hemorrhagic Telangiectasia.
Endoglin in angiogenesis and vascular diseases.
Endothelial depletion of Acvrl1 in mice leads to arteriovenous malformations associated with reduced endoglin expression.
Familial occurrence of brain arteriovenous malformation: a novel ACVRL1 mutation detected by whole exome sequencing.
Heart failure and pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia type 2.
Hereditary hemorrhagic telangiectasia: evidence for regional founder effects of ACVRL1 mutations in French and Italian patients.
Identification of hereditary hemorrhagic telangiectasia type 1 in newborns by protein expression and mutation analysis of endoglin.
Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation.
Intracranial hemorrhage in infants and children with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome).
Matrix Gla protein deficiency causes arteriovenous malformations in mice.
Mutation analysis in hereditary haemorrhagic telangiectasia in Germany reveals 11 novel ENG and 12 novel ACVRL1/ALK1 mutations.
Mutation analysis of "Endoglin" and "Activin receptor-like kinase" genes in German patients with hereditary hemorrhagic telangiectasia and the value of rapid genotyping using an allele-specific PCR-technique.
Overexpression of Activin Receptor-Like Kinase 1 in Endothelial Cells Suppresses Development of Arteriovenous Malformations in Mouse Models Of Hereditary Hemorrhagic Telangiectasia.
Prevalence of and Factors Associated with Arterial Aneurysms in Patients with Hereditary Hemorrhagic Telangiectasia: 17-year Retrospective Series of 418 Patients.
Pulmonary Hypertension in Hereditary Haemorrhagic Teleangiectasia.
Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (rendu-osler disease).
Reduced mural cell coverage and impaired vessel integrity after angiogenic stimulation in the Alk1-deficient brain.
Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT).
The ALK-1/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?
Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain.
[Genetic diagnostics of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease)].
Arthritis
A20 prevents inflammasome-dependent arthritis by inhibiting macrophage necroptosis through its ZnF7 ubiquitin-binding domain.
Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation.
Primary immunodeficiency with chronic enteropathy and developmental delay in a boy arising from a novel homozygous RIPK1 variant.
RIPK1 inhibition attenuates experimental autoimmune arthritis via suppression of osteoclastogenesis.
RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL.
TGF-beta type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody.
The caspase-8/RIPK3 signaling axis in antigen presenting cells controls the inflammatory arthritic response.
The p55TNFR-IKK2-Ripk3 axis orchestrates arthritis by regulating death and inflammatory pathways in synovial fibroblasts.
Arthritis, Experimental
Interferon-gamma regulates inflammatory cell death by targeting necroptosis in experimental autoimmune arthritis.
Modulation of TNFR 1-triggered two opposing signals for inflammation and apoptosis via RIPK 1 disruption by geldanamycin in rheumatoid arthritis.
Arthritis, Rheumatoid
A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.
Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation.
Up-regulated microRNA-411 or declined RIPK1 inhibits proliferation and promotes apoptosis of synoviocytes in rheumatoid arthritis mice via decreased NF-?B pathway.
Asthma
Airway epithelial cell necroptosis contributes to asthma exacerbation in a mouse model of house dust mite-induced allergic inflammation.
Association between Genetic Variations of Transforming Growth Factor Beta Receptor Type III and Asthma in a Korean Population.
Basal expression of bone morphogenetic protein receptor is reduced in mild asthma.
Gene-gene interaction in regulatory T-cell function in atopy and asthma development in childhood.
In vitro wounding of airway smooth muscle cell monolayers increases expression of TGF-beta receptors.
Increased TGF-beta2 in severe asthma with eosinophilia.
LRG1 downregulation in allergic airway disorders and its expression in peripheral blood and tissue cells.
Smads as intracellular mediators of airway inflammation.
Atherosclerosis
ALK5 deficiency inhibits macrophage inflammation and lipid loading by targeting KLF4.
Anti-inflammatory and anti-atherogenic role of BMP receptor II in atherosclerosis.
Anti-inflammatory and antiatherogenic role of BMP receptor II in endothelial cells.
Cell-specific and athero-protective roles for RIPK3 in a murine model of atherosclerosis.
Genomic locus proteomic screening identifies the NF-?B signaling pathway components NF?B1 and IKBKG as transcriptional regulators of Ripk3 in endothelial cells.
Impact of myeloid RIPK1 gene deletion on atherogenesis in ApoE-deficient mice.
Increased type II transforming growth factor-beta receptor expression in liver cells during cholesterol challenge.
Loss of MLKL (Mixed Lineage Kinase Domain-Like Protein) Decreases Necrotic Core but Increases Macrophage Lipid Accumulation in Atherosclerosis.
RIPK1 Expression Associates With Inflammation in Early Atherosclerosis in Humans and Can Be Therapeutically Silenced to Reduce NF-?B Activation and Atherogenesis in Mice.
RIPK1 targeting protects against obesity and atherosclerosis.
Serum levels of the TGF-beta receptor are increased in atherosclerosis.
The core-aldehyde 9-oxononanoyl cholesterol increases the level of transforming growth factor beta1-specific receptors on promonocytic U937 cell membranes.
Autoimmune Diseases
The latest information on the RIPK1 post-translational modifications and functions.
The Pseudokinase MLKL and the Kinase RIPK3 Have Distinct Roles in Autoimmune Disease Caused by Loss of Death-Receptor-Induced Apoptosis.
Autoimmune Lymphoproliferative Syndrome
Caspase-8 deficiency in mouse embryos triggers chronic RIPK1-dependent activation of inflammatory genes, independently of RIPK3.
Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis.
Mechanisms of necroptosis in T cells.
Bacterial Infections
EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation.
Kinase Activities of RIPK1 and RIPK3 Can Direct IFN-? Synthesis Induced by Lipopolysaccharide.
RIPK3 in cell death and inflammation: the good, the bad, and the ugly.
Bicuspid Aortic Valve Disease
Transforming growth factor-beta receptor type II mutation in a patient with bicuspid aortic valve disease and intraoperative aortic dissection.
Blister
Expression of TGF-beta receptor 1 and Smads in the tissues of primary spontaneous pneumothorax.
Bone Marrow Failure Disorders
Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis.
Bone Resorption
Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro.
Inhibition of RIPK1/RIPK3 ameliorates osteoclastogenesis through regulating NLRP3-dependent NF-?B and MAPKs signaling pathways.
Osteoblastic responses to TGF-beta during bone remodeling.
Pharmacologic Calcitriol Inhibits Osteoclast Lineage Commitment via the BMP-Smad1- I?B-NF-?B Pathway.
Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone.
Bowen's Disease
Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma.
Brain Edema
Cell-specific activation of RIPK1 and MLKL after intracerebral hemorrhage in mice.
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
Brain Injuries
Caspofungin Suppresses Brain Cell Necroptosis in Ischemic Stroke Rats via Up-Regulation of Pellino3.
Inhibiting of RIPK3 attenuates early brain injury following subarachnoid hemorrhage: Possibly through alleviating necroptosis.
Protective effect of mild-induced hypothermia against moderate traumatic brain injury in rats involved in necroptotic and apoptotic pathways.
The possible roles of necroptosis during cerebral ischemia and ischemia / reperfusion injury.
Brain Injuries, Traumatic
Functional suppression of Ripk1 blocks the NF-?B signaling pathway and induces neuron autophagy after traumatic brain injury.
Protective effect of mild-induced hypothermia against moderate traumatic brain injury in rats involved in necroptotic and apoptotic pathways.
RIPK1 or RIPK3 deletion prevents progressive neuronal cell death and improves memory function after traumatic brain injury.
Brain Ischemia
Necrostatin-1 Improves Long-term Functional Recovery Through Protecting Oligodendrocyte Precursor Cells After Transient Focal Cerebral Ischemia in Mice.
The possible roles of necroptosis during cerebral ischemia and ischemia / reperfusion injury.
Brain Neoplasms
A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report.
Breast Neoplasms
A kinase-defective transforming growth factor-beta receptor type II is a dominant-negative regulator for human breast carcinoma MCF-7 cells.
ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells.
An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.
Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features.
Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells.
BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation.
Bone morphogenetic protein-7 induces telomerase inhibition, telomere shortening, breast cancer cell senescence, and death via Smad3.
Control of type II transforming growth factor-beta receptor expression by integrin ligation.
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Deletion of one adenine base within the polyadenine tract of transforming growth factor-beta receptor type II in human MDA-MB-231 breast cancer cell line.
Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy.
Differential involvement of TAK1, RIPK1 and NF-?B signaling in Smac mimetic-induced cell death in breast cancer cells.
Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.
Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer.
EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.
Expression profile of agonistic Smads in human breast cancer cells: absence of regulation by estrogens.
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta.
Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta ) and the type II TGF-beta receptor.
HER-2/neu-Positive breast carcinoma: molecular concomitants by proteomic analysis and their therapeutic implications.
High-Throughput Assessment of Kinome-wide Activation States.
Induction of transforming growth factor-beta receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2'-deoxycytidine.
Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo.
Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor.
Int7G24A variant of transforming growth factor-beta receptor type I is associated with invasive breast cancer.
Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
Nodal and activin receptor-like kinase 7 induce apoptosis in human breast cancer cell lines: Role of caspase 3.
Overexpression of Activin Receptor-like Kinase 7 in Breast Cancer Cells Is Associated with Decreased Cell Growth and Adhesion.
PARP regulates TGF-beta receptor type II expression in estrogen receptor-positive breast cancer cell lines.
Pro-necrotic molecules impact local immunosurveillance in human breast cancer.
Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients.
Quantitative analysis of the secretome of TGF-beta Signaling-deficient mammary fibroblasts.
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis.
RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence.
Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion.
TGF-? signaling pathway and breast cancer susceptibility.
TGF-beta receptor mediated telomerase inhibition, telomere shortening and breast cancer cell senescence.
TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer.
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
TGF-beta signaling in breast cancer.
TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells.
TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer.
The RING finger protein11 binds to Smad4 and enhances Smad4-dependant TGF-beta signalling.
The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma.
The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.
The type III TGF-beta receptor suppresses breast cancer progression.
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells.
Transcriptional up-regulation of BMP-4 and BMPR-II genes in the peripheral blood of breast cancer patients: A pilot study.
Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer.
Transforming growth factor-?-induced lncRNA-Smad7 inhibits apoptosis of mouse breast cancer JygMC(A) cells.
Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model.
Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways.
Transforming growth factor-beta1 upregulates the expression of CXC chemokine receptor 4 (CXCR4) in human breast cancer MCF-7 cells.
ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer.
Bronchitis
Fine particulate matter (PM2.5) enhances airway hyperresponsiveness (AHR) by inducing necroptosis in BALB/c mice.
Burkitt Lymphoma
Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells.
Carcinogenesis
A RIPK3-PGE2 Circuit Mediates Myeloid-Derived Suppressor Cell-Potentiated Colorectal Carcinogenesis.
Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.
ALK7 Promotes Vascular Smooth Muscle Cells Phenotypic Modulation by Negative Regulating PPAR? Expression.
Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma.
Analysis of TGF-beta type I receptor for mutations and polymorphisms in head and neck cancers.
Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer.
BMPR2 inhibition induced apoptosis and autophagy via destabilization of XIAP in human chondrosarcoma cells.
Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells.
Chromosome 3p tumor-suppressor gene alterations in cervical carcinomas.
Coordinated functions of E-cadherin and transforming growth factor beta receptor II in vitro and in vivo.
Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis.
Defects of TGF-beta receptor signaling in mammary cell tumorigenesis.
Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis.
Epithelial HMGB1 Delays Skin Wound Healing and Drives Tumor Initiation by Priming Neutrophils for NET Formation.
Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development.
Expression of endoglin and the activin receptor-like kinase 1 in skin suggests a role for these receptors in normal skin function and skin tumorigenesis.
Expression of TGF-beta type II receptor antisense RNA impairs TGF-beta signaling in vitro and promotes mammary gland differentiation in vivo.
Expression of transforming growth factor beta1 and its type II receptor in mouse colon tumors induced by azoxymethane.
Finding a new role for NEMO: A key player in preventing hepatocyte apoptosis and liver tumorigenesis by inhibiting RIPK1.
Genetic alterations in the transforming growth factor receptor complex in sporadic endometrial carcinoma.
Genomic instability and colorectal cancer.
Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis.
Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis.
Lack of expression of transforming growth factor-beta type II receptor associated with malignant progression in human salivary gland cell clones.
Morphologic and molecular analysis of estrogen-induced pituitary tumorigenesis in targeted disruption of transforming growth factor-beta receptor type II and/or p27 mice.
Mutations of the transforming growth factor beta type II receptor gene and microsatellite instability in gastric cancer.
RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury.
RIPK1 binds MCU to mediate induction of mitochondrial Ca2+ uptake and promote colorectal oncogenesis.
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
RIPK3 orchestrates fatty acid metabolism in tumor-associated macrophages and hepatocarcinogenesis.
RIPK3 Suppresses the Progression of Spontaneous Intestinal Tumorigenesis.
Soluble transforming growth factor beta type II receptor attenuates TGF-beta1 activity in human colorectal cancer LoVo cells.
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer.
Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.
Tumour progression in experimental oral carcinogenesis is associated with changes in EGF and TGF-beta receptor expression and altered responses to these growth factors.
Carcinoma
A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma.
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
A transforming growth factor-beta receptor-interacting protein frequently mutated in human ovarian cancer.
ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder.
An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.
Analysis of TGF-beta type I receptor for mutations and polymorphisms in head and neck cancers.
Antitumor activity of ALK1 in pancreatic carcinoma cells.
Attenuated type II TGF-beta receptor signalling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination.
BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation.
Breast Cancer Special Feature: Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators.
Cellular growth inhibition by IGFBP-3 and TGF-beta1 requires LRP-1.
Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice.
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Coordinated functions of E-cadherin and transforming growth factor beta receptor II in vitro and in vivo.
Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Downregulation of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts.
Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma.
Effects of marine sponge extracts on mitogen-activated protein kinase (MAPK/ERK(1,2)) activity in SW-13 human adrenal carcinoma cells.
Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development.
Expression of TGF-alpha/EGF and TGF-beta receptors in human colon carcinoma cell lines.
Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
Expression of transforming growth factor beta type II receptors in head and neck squamous cell carcinoma.
Frequent aberration of the transforming growth factor-beta receptor II gene in cell lines but no apparent mutation in pre-invasive and invasive carcinomas of the uterine cervix.
Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells.
Function of the type V transforming growth factor beta receptor in transforming growth factor beta-induced growth inhibition of mink lung epithelial cells.
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
Genome-wide DNA methylation and RNA expression profiles identified RIPK3 as a differentially methylated gene in Chlamydia pneumoniae infection lung carcinoma patients in China.
Identification of genetic alterations in the TGFbeta type II receptor gene promoter.
Immunoexpression of bone morphogenetic protein-2 (BMP-2), BMP receptor type IA, and BMP receptor type II in metastatic and non-metastatic lower lip squamous cell carcinoma.
Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo.
Inhibition of TGF-beta1 suppresses motility and invasiveness of oral squamous cell carcinoma cell lines via modulation of integrins and down-regulation of matrix-metalloproteinases.
Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma.
Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines.
Lack of transforming growth factor-? signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.
Loss of expression of TGF-beta1, TbetaRI, and TbetaRII correlates with differentiation in human oral squamous cell carcinomas.
Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma.
Loss of p12CDK2-AP1 expression in human oral squamous cell carcinoma with disrupted transforming growth factor-beta-Smad signaling pathway.
Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia.
Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma.
Microarray analysis of promoter methylation in lung cancers.
Monocyte chemoattractant protein-1 is generated via TGF-beta by myofibroblasts in gastric intestinal metaplasia and carcinoma without H. pylori infection.
Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck.
Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.
Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma.
Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line.
Overexpression of transforming growth factor beta-type II receptor reduces tumorigenicity and metastastic potential of K-ras-transformed thyroid cells.
Phospho-?Np63?-responsive microRNAs contribute to the regulation of necroptosis in squamous cell carcinoma upon cisplatin exposure.
Reduced levels of transforming growth factor-beta type I receptor in human gastric carcinomas.
Relationship between intratumor histological heterogeneity and genetic abnormalities in gastric carcinoma with microsatellite instability.
RIPK1 contributes to cisplatin-induced apoptosis of esophageal squamous cell carcinoma cells via activation of JNK pathway.
RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1? release, and efficient paracrine dendritic cell activation.
Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma.
Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma.
The Expression of Activin Receptor-Like Kinase 1 among Patients with Head and Neck Cancer.
The Expression of Activin Receptor-like Kinase 1 in HNSCC.
Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
Transforming growth factor beta type I receptor acts as a potent tumor suppressor in rat bladder carcinoma.
Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer.
Transforming growth factor-beta expression in prostate neoplasia.
Transforming growth factor-beta promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1.
Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition.
Transforming growth factor-beta receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas.
Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas.
Transforming growth factor-beta type II receptors and smad proteins in follicular thyroid tumors.
Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder.
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
[Correlations of TGF-betaRII, Smad4 and Smad7 expression to clinicopathologic characteristics and prognosis of gastric cancer.]
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
Carcinoma, Basal Cell
Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
Carcinoma, Ductal
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
Carcinoma, Ehrlich Tumor
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Carcinoma, Embryonal
Activation of the murine type II transforming growth factor-beta receptor gene: up-regulation and function of the transcription factor Elf-3/Ert/Esx/Ese-1.
Differential expression of BMP receptors in early mouse development.
Transcriptional activation of the type II transforming growth factor-beta receptor gene upon differentiation of embryonal carcinoma cells.
Unique and selective effects of five Ets family members, Elf3, Ets1, Ets2, PEA3, and PU.1, on the promoter of the type II transforming growth factor-beta receptor gene.
Carcinoma, Hepatocellular
A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma.
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.
Activin receptor-like kinase-7 induces apoptosis through activation of MAPKs in a Smad3-dependent mechanism in hepatoma cells.
Biology of transforming growth factor beta in hepatocarcinogenesis.
Expression and genetic polymorphism of necroptosis related protein RIPK1 is correlated with severe hepatic ischemia-reperfusion injury and prognosis after hepatectomy in hepatocellular carcinoma patients.
Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-beta.
Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep40: inhibitory actions of vitamin K.
Hepatocyte-specific TAK1 deficiency drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and hepatocellular carcinoma.
Increased type II transforming growth factor-beta receptor expression in liver cells during cholesterol challenge.
Induction of angiogenesis by expression of soluble type II transforming growth factor-beta receptor in mouse hepatoma.
Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation.
Loss of endogenous TGF-beta effect induces mouse hepatoma malignancy by correlation with cyclooxygenase-2 and VEGF.
Mixed lineage kinase 3 (MLK3)-activated p38 MAP kinase mediates transforming growth factor-beta-induced apoptosis in hepatoma cells.
Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein.
NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis.
OTULIN Prevents Liver Inflammation and Hepatocellular Carcinoma by Inhibiting FADD- and RIPK1 Kinase-Mediated Hepatocyte Apoptosis.
Reduced transforming growth factor-beta receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis.
Relation of type II transforming growth factor-beta receptor to hepatic fibrosis and hepatocellular carcinoma.
RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma.
RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer.
RIPK3 mRNA level acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma.
Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma.
The enigma of RIPK1 in the liver: More than just a kinase.
Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
Carcinoma, Non-Small-Cell Lung
Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer.
Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines.
Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines.
Prognostic Significance of CHIP and RIPK3 in Non-Small Cell Lung Cancer.
TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.
Carcinoma, Ovarian Epithelial
Activin receptor-like kinase 7 induces apoptosis through up-regulation of Bax and down-regulation of Xiap in normal and malignant ovarian epithelial cell lines.
Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients.
MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance.
Nodal induces apoptosis and inhibits proliferation in human epithelial ovarian cancer cells via activin receptor-like kinase 7.
Carcinoma, Renal Cell
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma.
Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma.
The type III TGF-{beta} receptor regulates epithelial and cancer cell migration through {beta}-arrestin2-mediated activation of Cdc42.
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
Carcinoma, Small Cell
Microarray analysis of promoter methylation in lung cancers.
Carcinoma, Squamous Cell
A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression.
Coordinated functions of E-cadherin and transforming growth factor beta receptor II in vitro and in vivo.
Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
Expression of transforming growth factor beta type II receptors in head and neck squamous cell carcinoma.
Identification of genetic alterations in the TGFbeta type II receptor gene promoter.
Immunoexpression of bone morphogenetic protein-2 (BMP-2), BMP receptor type IA, and BMP receptor type II in metastatic and non-metastatic lower lip squamous cell carcinoma.
Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma.
Loss of expression of TGF-beta1, TbetaRI, and TbetaRII correlates with differentiation in human oral squamous cell carcinomas.
Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia.
Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck.
Phospho-?Np63?-responsive microRNAs contribute to the regulation of necroptosis in squamous cell carcinoma upon cisplatin exposure.
RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1? release, and efficient paracrine dendritic cell activation.
TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma.
The Expression of Activin Receptor-Like Kinase 1 among Patients with Head and Neck Cancer.
The Expression of Activin Receptor-like Kinase 1 in HNSCC.
Cardiomegaly
BMP TYPE I RECEPTOR ALK2 IS REQUIRED FOR ANGIOTENSIN II-INDUCED CARDIAC HYPERTROPHY.
Critical role of X-box binding protein 1 in NADPH oxidase 4-triggered cardiac hypertrophy is mediated by receptor interacting protein kinase 1.
Cardiomyopathies
[Pulmonary hypertension: from genetics to treatments]
Cardiomyopathy, Dilated
A new discovered gene mutation in a child with dilated cardiomyopathy.
Cardiovascular Diseases
ALK7 Promotes Vascular Smooth Muscle Cells Phenotypic Modulation by Negative Regulating PPAR? Expression.
Generation of a floxed allele of the mouse BMP type II receptor gene.
Genetic modifiers interact with maternal determinants in vascular development of Tgfb1(-/-) mice.
Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms.
Silencing of activin receptor-like kinase 7 alleviates aortic stiffness in type 2 diabetic rats.
The ALK-1/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?
The Role of RIPK1 and RIPK3 in Cardiovascular Disease.
caspase-8 deficiency
Caspase-8 deficiency in mouse embryos triggers chronic RIPK1-dependent activation of inflammatory genes, independently of RIPK3.
Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis.
Mechanisms of necroptosis in T cells.
RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis.
caspase-9 deficiency
Caspase-9 acts as a regulator of necroptotic cell death.
Castleman Disease
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor.
Cataract
Immunolocalization of TGF-beta1, -beta2, and -beta3, and TGF-beta receptors in human lens capsules with lens implants.
Cerebral Hemorrhage
Cell-specific activation of RIPK1 and MLKL after intracerebral hemorrhage in mice.
Genetic Inhibition of Receptor Interacting Protein Kinase-1 Reduces Cell Death and Improves Functional Outcome After Intracerebral Hemorrhage in Mice.
Sequential activation of necroptosis and apoptosis cooperates to mediate vascular and neural pathology in stroke.
Cerebrovascular Disorders
Role of activin receptor-like kinase 1 in vascular development and cerebrovascular diseases.
Chlamydophila Infections
Genome-wide DNA methylation and RNA expression profiles identified RIPK3 as a differentially methylated gene in Chlamydia pneumoniae infection lung carcinoma patients in China.
Cholangiocarcinoma
In situ detection of TGF betas, TGF beta receptor II mRNA and telomerase activity in rat cholangiocarcinogenesis.
[Expression of Smad4 and transforming growth factor-beta1, transforming growth factor-beta receptor II in cholangiocarcinoma tissue and its biological siginificance]
Cholangitis
B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice.
Beta-glucosylceramide ameliorates liver inflammation in murine autoimmune cholangitis.
Inactivation of caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis.
Cholestasis
Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injury.
I?B kinase?/? control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell-death mediator receptor-interacting protein kinase 1.
Chondrosarcoma
BMPR2 inhibition induced apoptosis and autophagy via destabilization of XIAP in human chondrosarcoma cells.
BMPR2-pSMAD1/5 signaling pathway regulates RUNX2 expression and impacts the progression of dedifferentiated chondrosarcoma.
Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone.
Choriocarcinoma
Endoglin, a component of the TGF-beta receptor system, is a differentiation marker of human choriocarcinoma cells.
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Choroidal Neovascularization
Expression of transforming growth factor-beta receptors in normal rat retina and experimental choroidal neovascularization.
Chronic Periodontitis
Loss of periodontal ligament fibroblasts by RIPK3-MLKL-mediated necroptosis in the progress of chronic periodontitis.
Classical Swine Fever
Viral strategies for triggering and manipulating mitophagy.
Cleft Lip
Transforming growth factor-beta receptor type 1 (TGFBR1) is not associated with non-syndromic cleft lip with or without cleft palate in patients of Central European descent.
Cleft Palate
All-trans retinoic acid inhibited chondrogenesis of mouse embryonic palate mesenchymal cells by down-regulation of TGF-beta/Smad signaling.
Tissue-specific expression of Cre recombinase from the Tgfb3 locus.
Transforming growth factor-beta receptor type 1 (TGFBR1) is not associated with non-syndromic cleft lip with or without cleft palate in patients of Central European descent.
[The preliminary study on transforming growth factor-beta 3, activin receptor-like kinase 5 expression in 2, 3, 7, 8-tetrachloro-p-dibenzodioxin and dexamethasone induced palatal cleft in mice]
Colitis
A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways.
A pan-RAF inhibitor LY3009120 inhibits necroptosis by preventing phosphorylation of RIPK1 and alleviates dextran sulfate sodium-induced colitis.
B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice.
Gut epithelial TSC1/mTOR controls RIPK3-dependent necroptosis in intestinal inflammation and cancer.
Inhibition of RIPK3 Pathway Attenuates Intestinal Inflammation and Cell Death of Inflammatory Bowel Disease and Suppresses Necroptosis in Peripheral Mononuclear Cells of Ulcerative Colitis Patients.
Necroptosis is dispensable for the development of inflammation-associated or sporadic colon cancer in mice.
NEMO Prevents RIP Kinase 1-Mediated Epithelial Cell Death and Chronic Intestinal Inflammation by NF-?B-Dependent and -Independent Functions.
RIPK1 inhibitor ameliorates colitis by directly maintaining intestinal barrier homeostasis and regulating following IECs-immuno crosstalk.
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
The enhanced susceptibility of ADAM-17 hypomorphic mice to DSS-induced colitis is not ameliorated by loss of RIPK3, revealing an unexpected function of ADAM-17 in necroptosis.
The scaffold-dependent function of RIPK1 in dendritic cells promotes injury-induced colitis.
Traditional herbal formula Wu-Mei-Wan alleviates TNBS-induced colitis in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation.
Z-nucleic-acid sensing triggers ZBP1-dependent necroptosis and inflammation.
Colitis, Ulcerative
A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.
Emerging views of mitophagy in immunity and autoimmune diseases.
How autophagy controls the intestinal epithelial barrier.
Inhibition of RIPK3 Pathway Attenuates Intestinal Inflammation and Cell Death of Inflammatory Bowel Disease and Suppresses Necroptosis in Peripheral Mononuclear Cells of Ulcerative Colitis Patients.
Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation.
Colonic Neoplasms
A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma.
Adenosine induces apoptosis through TNFR1/RIPK1/P38 axis in colon cancer cells.
Cationic peroxidase from proso millet induces human colon cancer cell necroptosis by regulating autocrine TNF-? and RIPK3 demethylation.
Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death.
Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma.
Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer.
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.
Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.
Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level.
Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population.
Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III.
Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations.
RIPK1 binds MCU to mediate induction of mitochondrial Ca2+ uptake and promote colorectal oncogenesis.
RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer.
RUNX3 inhibits cell proliferation and induces apoptosis by TGF-beta-dependent and -independent mechanisms in human colon carcinoma cells.
Soluble transforming growth factor beta type II receptor attenuates TGF-beta1 activity in human colorectal cancer LoVo cells.
TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway.
The Fragile X Mental Retardation Protein Regulates RIPK1 and Colorectal Cancer Resistance to Necroptosis.
Transfection of the type II TGF-beta receptor into colon cancer cells increases receptor expression, inhibits cell growth, and reduces the malignant phenotype.
Transforming growth factor-beta receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas.
Uncommon TGFBRI allele is not associated with increased susceptibility to colon cancer.
Colorectal Neoplasms
A RIPK3-PGE2 Circuit Mediates Myeloid-Derived Suppressor Cell-Potentiated Colorectal Carcinogenesis.
Autocrine BMP-4 Signaling Is a Therapeutic Target in Colorectal Cancer.
CircFAM120B Blocks the Development of Colorectal Cancer by Activating TGF-Beta Receptor II Expression via Targeting miR-645.
Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis.
Expression of TGF-beta1, TbetaRII and Smad4 in colorectal carcinoma.
Expression of transforming growth factor beta receptors in normal human colon and sporadic adenocarcinomas.
Function of the type V transforming growth factor beta receptor in transforming growth factor beta-induced growth inhibition of mink lung epithelial cells.
Growth inhibition due to complementation of transforming growth factor-beta receptor type II-defect by human chromosome 3 transfer in human colorectal carcinoma cells.
How autophagy controls the intestinal epithelial barrier.
Induction of the expression of genes encoding TGF-beta isoforms and their receptors by inositol hexaphosphate in human colon cancer cells.
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
RIPK1 and CASP7 polymorphism as prognostic markers for survival in patients with colorectal cancer after complete resection.
RIPK1 binds MCU to mediate induction of mitochondrial Ca2+ uptake and promote colorectal oncogenesis.
RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping.
Somatic frameshift mutations of bone morphogenic protein receptor 2 gene in gastric and colorectal cancers with microsatellite instability.
TGF-beta signaling alterations and susceptibility to colorectal cancer.
TGFBR1 variants TGFBR1(*)6A and Int7G24A are not associated with an increased familial colorectal cancer risk.
TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
The Fragile X Mental Retardation Protein Regulates RIPK1 and Colorectal Cancer Resistance to Necroptosis.
The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study.
The mannose 6-phosphate/insulin-like growth factor-II receptor is a substrate of type V transforming growth factor-beta receptor.
The type II transforming growth factor-beta receptor as a tumor-suppressor gene.
Communicable Diseases
Initiation and execution mechanisms of necroptosis: an overview.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Augmented BMP signaling commits cranial neural crest cells to a chondrogenic fate by suppressing autophagic ?-catenin degradation.
Connective Tissue Diseases
High prevalence of vertebral artery tortuosity of Loeys-Dietz syndrome in comparison with Marfan syndrome.
Lack of circulating autoantibodies to bone morphogenetic protein receptor-II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension.
Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease.
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Small platelet microparticle levels are increased in pulmonary arterial hypertension.
[Pulmonary arterial hypertension]
Contracture
Controlled release of transforming growth factor-beta receptor kinase inhibitor from thermosensitive Chitosan-based hydrogel: application for prevention of capsular contracture.
Coronary Artery Disease
RIPK1 Expression Associates With Inflammation in Early Atherosclerosis in Humans and Can Be Therapeutically Silenced to Reduce NF-?B Activation and Atherogenesis in Mice.
Sequence Variants in BMPR2 and Genes Involved in the Serotonin and Nitric Oxide Pathways in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Relation to Clinical Parameters and Comparison with Left Heart Disease.
COVID-19
Primidone blocks RIPK1-driven cell death and inflammation.
Craniosynostoses
Augmentation of Smad-dependent BMP signaling in neural crest cells causes craniosynostosis in mice.
Toward an understanding of nonsyndromic craniosynostosis: altered patterns of TGF-beta receptor and FGF receptor expression induced by intrauterine head constraint.
CREST Syndrome
Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease.
Crohn Disease
Decreased Colonic Activin Receptor-Like Kinase 1 Disrupts Epithelial Barrier Integrity in Patients With Crohn's Disease.
Emerging views of mitophagy in immunity and autoimmune diseases.
How autophagy controls the intestinal epithelial barrier.
Cystic Fibrosis
How autophagy controls the intestinal epithelial barrier.
Cysts
A high throughput zebrafish chemical screen reveals ALK5 and non-canonical androgen signalling as modulators of the pkd2-/- phenotype.
Enhanced resistance to soybean cyst nematode Heterodera glycines in transgenic soybean by silencing putative CLE receptors.
JNK signaling prevents biliary cyst formation through a CASPASE-8-dependent function of RIPK1 during aging.
Synergistic Interaction of CLAVATA1, CLAVATA2, and RECEPTOR-LIKE PROTEIN KINASE 2 in Cyst Nematode Parasitism of Arabidopsis.
Dehydration
Identification of a receptor-like protein kinase gene rapidly induced by abscisic acid, dehydration, high salt, and cold treatments in Arabidopsis thaliana.
Demyelinating Diseases
Cornel Iridoid Glycoside Ameliorated Alzheimer's Disease-Like Pathologies and Necroptosis through RIPK1/MLKL Pathway in Young and Aged SAMP8 Mice.
Modulation of vigabatrin induced cerebellar injury: the role of caspase-3 and RIPK1/RIPK3-regulated cell death pathways.
Dengue
Viral strategies for triggering and manipulating mitophagy.
Dermatitis
Inhibitor of Apoptosis Proteins (Iaps) Limit Ripk1 Mediated Skin Inflammation.
LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L.
Diabetes Complications
Knockdown of ALK7 inhibits high glucose-induced oxidative stress and apoptosis in retinal pigment epithelial cells.
Diabetes Mellitus
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension.
RIPK3 blockade attenuates tubulointerstitial fibrosis in a mouse model of diabetic nephropathy.
Silencing of activin receptor-like kinase 7 alleviates aortic stiffness in type 2 diabetic rats.
Diabetes Mellitus, Type 2
DNA Sequence Variation in ACVR1C Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes.
Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes.
Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression.
Silencing of activin receptor-like kinase 7 alleviates aortic stiffness in type 2 diabetic rats.
When Beauty Is Skin Deep: Regulation of the Wound Response by Caspase-8, RIPK3, and the Inflammasome.
Diabetic Cardiomyopathies
Knockdown of ALK7 inhibits high glucose-induced oxidative stress and apoptosis in retinal pigment epithelial cells.
Diabetic Foot
Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers.
Diabetic Nephropathies
RIPK3 blockade attenuates tubulointerstitial fibrosis in a mouse model of diabetic nephropathy.
Transcription factor 7-like 2 (TCF7L2) regulates activin receptor-like kinase 1 (ALK1)/Smad1 pathway for development of diabetic nephropathy.
Diffuse Intrinsic Pontine Glioma
Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of 11C-Labeled ALK2 Inhibitors.
Dyspnea
Accuracy of Echocardiography to Evaluate Pulmonary Vascular and RV Function During Exercise.
Eisenmenger Complex
Eisenmenger syndrome and atrial septal defect: nature or nurture?
Encephalitis
RIPK3 Restricts Viral Pathogenesis via Cell Death-Independent Neuroinflammation.
Endometrial Neoplasms
Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.
Activin A inhibits growth-inhibitory signals by TGF-beta1 in differentiated human endometrial adenocarcinoma cells.
Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium.
Genetic alterations in the transforming growth factor receptor complex in sporadic endometrial carcinoma.
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.
Endometriosis
BMP-6 and SMAD4 gene expression is altered in cumulus cells from women with endometriosis-associated infertility.
Endotoxemia
Caspase-8 Collaborates with Caspase-11 to Drive Tissue Damage and Execution of Endotoxic Shock.
Epilepsy
Increased expression of TGF-beta type I receptor in brain tissues of patients with temporal lobe epilepsy.
Overexpressed microRNA-494 represses RIPK1 to attenuate hippocampal neuron injury in epilepsy rats by inactivating the NF-?B signaling pathway.
Epilepsy, Temporal Lobe
Increased expression of TGF-beta type I receptor in brain tissues of patients with temporal lobe epilepsy.
Epistaxis
Clinical and molecular characterization of patients with hereditary hemorrhagic telangiectasia: Experience from an HHT Center of Excellence.
Hereditary haemorrhagic telangiectasia: A case report.
Hereditary hemorrhagic telangiectasia is caused by the Q490X mutation of the ACVRL1 gene in a large Arab family: support of homozygous lethality.
Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology.
Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia.
Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells.
Thoracic endografting in a patient with hereditary hemorrhagic telangiectasia presenting with a descending thoracic aneurysm.
[Gene diagnosis and treatment of hereditary hemorrhagic telangiectasia with epistaxis as its main symptom].
Esophageal Neoplasms
Connective tissue growth factor gene expression alters tumor progression in esophageal cancer.
Receptor interactive protein kinase 3 promotes Cisplatin-triggered necrosis in apoptosis-resistant esophageal squamous cell carcinoma cells.
Esophageal Squamous Cell Carcinoma
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
RIPK1 contributes to cisplatin-induced apoptosis of esophageal squamous cell carcinoma cells via activation of JNK pathway.
Essential Hypertension
Association of the gene polymorphisms of BMPR2, ACVRL1, SMAD9 and their interactions with the risk of essential hypertension in the Chinese Han population.
Extranodal Extension
Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Eye Abnormalities
Distinct developmental programs require different levels of Bmp signaling during mouse retinal development.
Familial Primary Pulmonary Hypertension
15 years journey of idiopathic pulmonary arterial hypertension with BMPR2 mutation.
4PBA Restores Signaling of a Cysteine-substituted Mutant BMPR2 Receptor Found in Patients with Pulmonary Arterial Hypertension.
A novel BMPR2 mutation in a patient with heritable pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia: A case report.
A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype.
A potential functional association between mutant BMPR2 and primary ovarian insufficiency.
Abnormal trafficking of endogenously expressed BMPR2 mutant allelic products in patients with heritable pulmonary arterial hypertension.
Alu-mediated nonallelic homologous and nonhomologous recombination in the BMPR2 gene in heritable pulmonary arterial hypertension.
BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia.
BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension.
BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension.
BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension.
BMPR2 Mutation-independent Mechanisms of Disrupted BMP Signaling in IPAH.
BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension.
BMPR2 mutations have short lifetime expectancy in primary pulmonary hypertension.
Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells.
Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.
Bone morphogenetic protein receptor-II mutation Arg491Trp causes malignant phenotype of familial primary pulmonary hypertension.
Bone morphogenetic protein type II receptor mutations causing protein misfolding in heritable pulmonary arterial hypertension.
Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of BMPRII.
Comparative analysis of BMPR2 gene and its mutations in idiopathic pulmonary arterial hypertension.
Correction of Nonsense BMPR2 and SMAD9 Mutations by Ataluren in Pulmonary Arterial Hypertension.
CORRIGENDUM: Alu-mediated nonallelic homologous and nonhomologous recombination in the BMPR2 gene in heritable pulmonary arterial hypertension.
Cytokines trigger disruption of endothelium barrier function and p38 MAP kinase activation in BMPR2-silenced human lung microvascular endothelial cells.
De novo mutations in the BMPR2 gene in patients with heritable pulmonary arterial hypertension.
Developments in therapeutics for pulmonary arterial hypertension.
Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1.
Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension.
Echocardiographic screening discloses increased values of pulmonary artery systolic pressure in 9 of 68 unselected patients affected with hereditary hemorrhagic telangiectasia.
Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension.
Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells.
Extensive pulmonary sarcoid reaction in a patient with BMPR-2 associated idiopathic pulmonary arterial hypertension.
Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein tùype II receptor.
Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension.
Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension.
Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension.
Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: a meta-analysis.
Generation of a floxed allele of the mouse BMP type II receptor gene.
Genotype-phenotype effects of Bmpr2 mutations on disease severity in mouse models of pulmonary hypertension.
Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension.
Growth, development, and phenotypic spectrum of individuals with deletions of 2q33.1 involving SATB2.
Heritable pulmonary hypertension: from bench to bedside.
Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium.
HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells.
Hypermethylation of BMPR2 Promoter Occurs in the Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression.
Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells.
Identities and frequencies of BMPR2 mutations in Chinese patients with idiopathic pulmonary arterial hypertension.
Idiopathic pulmonary arterial hypertension associated with a novel frameshift mutation in the bone morphogenetic protein receptor II gene and enhanced bone morphogenetic protein signaling: A case report.
Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity.
Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension.
Missense Mutations of the BMPR1B (ALK6) Gene in Childhood Idiopathic Pulmonary Arterial Hypertension.
Molecular Analysis of BMPR2, TBX4, and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families With Idiopathic and Hereditary Pulmonary Arterial Hypertension.
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
Monocrotaline pyrrole induces Smad nuclear accumulation and altered signaling expression in human pulmonary arterial endothelial cells.
Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.
N-linked glycosylation of the bone morphogenetic protein receptor type 2 (BMPR2) enhances ligand binding.
Novel nonsense mutation of the BMPR-II gene in a Japanese patient with familial primary pulmonary hypertension.
Outcomes of Childhood Pulmonary Arterial Hypertension in BMPR2 and ALK1 Mutation Carriers.
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia.
Primary pulmonary hypertension may be a heterogeneous disease with a second locus on chromosome 2q31.
Recent insights into the pathogenesis and therapeutics of pulmonary hypertension.
Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation.
Sequence Variants in BMPR2 and Genes Involved in the Serotonin and Nitric Oxide Pathways in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Relation to Clinical Parameters and Comparison with Left Heart Disease.
Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension.
Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.
The BMP type II receptor is located in lipid rafts, including caveolae, of pulmonary endothelium in vivo and in vitro.
The transforming growth factor-?-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease.
Transforming growth factor beta/bone morphogenic protein signaling in pulmonary arterial hypertension: remodeling revisited.
Transforming growth factor-betas and vascular disorders.
Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension.
Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension.
[Pulmonary hypertension: pathophysiology, genetics and functional genomics]
Fatty Liver
Inhibition of MLKL Attenuates Necroptotic Cell Death in a Murine Cell Model of Ischaemia Injury.
NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis.
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
Fetal Death
BMPR2 is required for postimplantation uterine function and pregnancy maintenance.
Fetal Growth Retardation
Key players of the necroptosis pathway RIPK1 and SIRT2 are altered in placenta from preeclampsia and fetal growth restriction.
Fibroadenoma
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
Fibroma
Paratesticular fibrous pseudotumor: a morphologic and immunohistochemical study of 13 cases.
Foot Ulcer
Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers.
Fragile X Syndrome
BMP signaling turns up in fragile X syndrome: FMRP represses BMPR2.
Gallbladder Neoplasms
Smac mimetic promotes TNF-? to induce apoptosis of gallbladder carcinoma cells.
Gastroenteritis
Viral strategies for triggering and manipulating mitophagy.
Gastrointestinal Neoplasms
Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic human gastrointestinal cancer.
Gaucher Disease
c-Abl activates RIPK3 signaling in Gaucher disease.
RIPK3 as a potential therapeutic target for Gaucher's disease.
Genetic Diseases, Inborn
ENG mutational mosaicism in a family with hereditary hemorrhagic telangiectasia.
Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.
Non-invasive CT screening for pulmonary arteriovenous malformations in children with confirmed hereditary hemorrhagic telangiectasia: Results from two pediatric centers.
Pathogenesis of Brain Arteriovenous Malformations.
Patients with Hereditary Hemorrhagic Telangectasia (HHT) Exhibit a Deficit of Polymorphonuclear Cell and Monocyte Oxidative Burst and Phagocytosis: A Possible Correlation with Altered Adaptive Immune Responsiveness in HHT.
Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology.
The unique activity of bone morphogenetic proteins in bone: a critical role of the Smad signaling pathway.
Transforming growth factor ?--at the centre of systemic sclerosis.
Gestational Trophoblastic Disease
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Gingival Overgrowth
Expression of transforming growth factor-beta receptor II mRNA in cyclosporine-induced gingival overgrowth.
Glaucoma
A novel RIPK1 inhibitor that prevents retinal degeneration in a rat glaucoma model.
Evaluation of Chitosan/Aptamer Targeting TGF-? Receptor II Thermo-Sensitive Gel for Scarring in Rat Glaucoma Filtration Surgery.
Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders.
Severe open angle glaucoma in hereditary hemorrhagic telangiectasia.
Thermoreversible gel for delivery of activin receptor-like kinase 5 inhibitor SB-505124 for glaucoma filtration surgery.
Glaucoma, Open-Angle
Severe open angle glaucoma in hereditary hemorrhagic telangiectasia.
Glioblastoma
Alkoxyamines: toward a new family of theranostic agents against cancer.
Integrative Network Analysis Combined with Quantitative Phosphoproteomics Reveals Transforming Growth Factor-beta Receptor type-2 (TGFBR2) as a Novel Regulator of Glioblastoma Stem Cell Properties.
Multiple forms of protein kinase from normal human brain and glioblastoma.
Necroptosis is associated with low procaspase-8 and active RIPK1 and -3 in human glioma cells.
Prognostic role of ALK-1 and h-TERT expression in glioblastoma multiforme: correlation with ALK gene alterations.
Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma.
Glioma
A new glioma grading model based on histopathology and Bone Morphogenetic Protein 2 mRNA expression.
Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma.
Expression of transforming-growth-factor (TGF)-beta receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-beta1.
Extracellular miRNA-21 as a novel biomarker in glioma: Evidence from meta-analysis, clinical validation and experimental investigations.
Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of 11C-Labeled ALK2 Inhibitors.
Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas.
MiR-135a functions as a selective killer of malignant glioma.
Necroptosis is associated with low procaspase-8 and active RIPK1 and -3 in human glioma cells.
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Protein kinase translocation following beta-adrenergic receptor activation in C6 glioma cells.
Resistance of Glioblastoma-Initiating Cells to Radiation Mediated by the Tumor Microenvironment Can Be Abolished by Inhibiting Transforming Growth Factor-?.
RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping.
SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma.
Glomerulonephritis
RIPK3-deficient mice were not protected from nephrotoxic nephritis.
Glomerulonephritis, IGA
Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis.
Glomerulonephritis, Membranoproliferative
Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis.
Glomerulonephritis, Membranous
Immunoelectron microscopic study on type I, II and III TGF-beta receptors on visceral glomerular epithelial cells in relation to glomerular basement membrane alterations in proteinuric rats.
Glucose Intolerance
The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance.
Gout
PMA and crystal-induced neutrophil extracellular trap formation involves RIPK1-RIPK3-MLKL signaling.
Granuloma
RIPK1-dependent apoptosis bypasses pathogen blockade of innate signaling to promote immune defense.
[Influence of interferon gamma treatment on expression of TGF-beta1 and its receptors in liver fibrosis of mice with schistosomiasis japonica]
Graves Disease
Functional assessment of the BMPR2 gene in lymphoblastoid cell lines from Graves' disease patients.
Head and Neck Neoplasms
Analysis of TGF-beta type I receptor for mutations and polymorphisms in head and neck cancers.
The Expression of Activin Receptor-Like Kinase 1 among Patients with Head and Neck Cancer.
Heart Defects, Congenital
5'UTR Repeat Polymorphisms of the BMPR2 gene in Children with Pulmonary Hypertension associated with Congenital Heart Disease.
BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension.
BMPR2 mutation is a potential predisposing genetic risk factor for congenital heart disease associated pulmonary vascular disease.
BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.
Genetics and genomics of pulmonary arterial hypertension.
Improvement of pulmonary arterial hypertension following medication and shunt closure in a BMPR2 mutation carrier with atrial septal defect.
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension.
[Pulmonary arterial hypertension]
Heart Diseases
Changes in plasma levels of RIPK1, RIPK3, and MLKL in patients with coronary atherosclerotic heart disease and its clinical predictive value.
Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
Sequence Variants in BMPR2 and Genes Involved in the Serotonin and Nitric Oxide Pathways in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Relation to Clinical Parameters and Comparison with Left Heart Disease.
Serum levels of the TGF-beta receptor are increased in atherosclerosis.
Heart Failure
Conditional knockout of activin like kinase-1 (ALK-1) leads to heart failure without maladaptive remodeling.
Expression of bone morphogenetic protein 4 and its receptors in the remodeling heart.
Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension.
Reduced activin receptor-like kinase 1 activity promotes cardiac fibrosis in heart failure.
RIPK3 Induces Cardiomyocyte Necroptosis via Inhibition of AMPK-Parkin-Mitophagy in Cardiac Remodelling after Myocardial Infarction.
Heart Septal Defects, Atrial
Improvement of pulmonary arterial hypertension following medication and shunt closure in a BMPR2 mutation carrier with atrial septal defect.
The Efficacy of a Genetic Analysis of the BMPR2 Gene in a Patient with Severe Pulmonary Arterial Hypertension and an Atrial Septal Defect Treated with Bilateral Lung Transplantation.
Hemochromatosis
Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors.
The hemochromatosis protein HFE signals predominantly via the BMP type I receptor ALK3 in vivo.
Hemoptysis
Risk factors for hemoptysis in idiopathic and hereditary pulmonary arterial hypertension.
Hepatitis
Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis.
RIPK1 protects from TNF-?-mediated liver damage during hepatitis.
RIPK1 protects hepatocytes from death in Fas-induced hepatitis.
RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis.
Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis.
The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis.
TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation.
Hepatitis A
Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis.
Hepatitis B
Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis.
RIPK3 mRNA level acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma.
Hepatitis B, Chronic
RIPK3 mRNA level acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma.
[The expression of transforming growth factor-beta receptor I and its mRNA in liver tissues of chronic hepatitis B and the clinical significance]
Hepatitis C, Chronic
Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats.
Serum level of transforming growth factor-beta1 (TGF-beta1) and the expression of TGF-beta receptor type II in peripheral blood mononuclear cells in patients with autoimmune hepatitis.
Hernias, Diaphragmatic, Congenital
Mutations in BMPR2 are not present in patients with pulmonary hypertension associated with congenital diaphragmatic hernia.
Herpes Simplex
Caspase-8 restricts antiviral CD8 T cell hyperaccumulation.
Viral strategies for triggering and manipulating mitophagy.
Herpes Zoster
Cloning and expression of a cDNA encoding mouse endoglin, an endothelial cell TGF-beta ligand.
Herpesviridae Infections
Remarkably Robust Antiviral Immune Response despite Combined Deficiency in Caspase-8 and RIPK3.
Hydatidiform Mole
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Hydrocephalus
Evidence for the involvement of caspases in establishing proper cerebrospinal fluid hydrodynamics.
Hyperandrogenism
Alteration of TGFB1, GDF9, and BMPR2 gene expression in preantral follicles of an estradiol valerate-induced polycystic ovary mouse model can lead to anovulation, polycystic morphology, obesity, and absence of hyperandrogenism.
Single-cell expression analysis of BMP15 and GDF9 in mature oocytes and BMPR2 in cumulus cells of women with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation.
Hypercholesterolemia
Increased type II transforming growth factor-beta receptor expression in liver cells during cholesterol challenge.
Hyperglycemia
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension.
Hyperinsulinism
Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension.
Hyperlipidemias
[Hyperlipidemia induced by high fat diet ingestion activates TGF-beta/Smad signaling pathway in the kidney of diabetic rats]
Hypersensitivity
A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1.
Hypertension
15 years journey of idiopathic pulmonary arterial hypertension with BMPR2 mutation.
4PBA Restores Signaling of a Cysteine-substituted Mutant BMPR2 Receptor Found in Patients with Pulmonary Arterial Hypertension.
5-HTT, BMPR2, EDN1, ENG, KCNA5 gene polymorphisms and susceptibility to pulmonary arterial hypertension: A meta-analysis.
A burden of rare variants in BMPR2 and KCNK3 contributes to a risk of familial pulmonary arterial hypertension.
A dual-light reporter system to determine the efficiency of protein-protein interactions in mammalian cells.
A novel BMPR2 mutation associated with pulmonary arterial hypertension in an octogenarian.
A novel BMPR2 mutation in a patient with heritable pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia: A case report.
A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype.
A novel break point of the BMPR2 gene exonic deletion in a patient with pulmonary arterial hypertension.
A novel mutation in the BMPR2 gene in familial pulmonary arterial hypertension.
A novel piperidine identified by stem cell-based screening attenuates pulmonary arterial hypertension by regulating BMP2 and PTGS2 levels.
A potential functional association between mutant BMPR2 and primary ovarian insufficiency.
Abnormal trafficking of endogenously expressed BMPR2 mutant allelic products in patients with heritable pulmonary arterial hypertension.
Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension.
Activin receptor-like kinase 1 is essential for placental vascular development in mice.
ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension.
Alu-mediated nonallelic homologous and nonhomologous recombination in the BMPR2 gene in heritable pulmonary arterial hypertension.
AN HOMOZYGOUS MUTATION IN KCNK3 IS ASSOCIATED WITH AN AGGRESSIVE FORM OF HEREDITARY PULMONARY ARTERIAL HYPERTENSION.
Approaches to treat pulmonary arterial hypertension by targeting bmpr2 - from cell membrane to nucleus.
BMP and activin type-II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.
BMP Pathway Regulation of and by Macrophages.
BMP9 and BMP10: two close vascular quiescence partners that stand out.
BMPR-II mutations promote pulmonary arterial hypertension via a hyperinflammatory response.
BMPR2 expression is suppressed by signaling through the estrogen receptor.
BMPR2 gene mutation in pulmonary arteriovenous malformation and pulmonary hypertension: a case report.
BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension.
BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension.
Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension.
BMPR2 mutation and outcome in pulmonary arterial hypertension: clinical relevance to physicians and patients.
BMPR2 Mutation Carriers: Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension Without Symptoms: Cautionary Tales?
BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia.
BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension.
BMPR2 Mutation-independent Mechanisms of Disrupted BMP Signaling in IPAH.
BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.
BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.
BMPR2 Mutations Influence Phenotype More Obviously in Male Patients with Pulmonary Arterial Hypertension.
BMPR2 Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients.
BMPRII deficiency impairs apoptosis via the BMPRII-ALK1-BclX-mediated pathway in pulmonary arterial hypertension.
Bone morphogenetic protein receptor II is a novel mediator of eNOS activation.
Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.
Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors.
Bone morphogenetic protein signaling is required for RAD51-mediated maintenance of genome integrity in vascular endothelial cells.
Bone morphogenetic protein type II receptor mutations causing protein misfolding in heritable pulmonary arterial hypertension.
Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of BMPRII.
Characterization of the BMPR2 5'-untranslated region and a novel mutation in pulmonary hypertension.
Clinical characteristics and survival of Chinese patients diagnosed with pulmonary arterial hypertension who carry BMPR2 or EIF2KAK4 variants.
Clinical Features of Pulmonary Arterial Hypertension in Young People with an ALK1 Mutation and Hereditary Hemorrhagic Telangiectasia.
Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension.
Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.
Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.
Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2.
Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension.
Comparative analysis of BMPR2 gene and its mutations in idiopathic pulmonary arterial hypertension.
Connectivity Map Analysis of NMD+ BMPR2 Related HPAH Provides Insights into Disease Penetrance.
Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension.
Contribution of oxidative stress to endothelial dysfunction in hereditary hemorrhagic telangiectasia.
Contributions of BMPR2 Mutations and Extrinsic Factors to Cellular Phenotypes of Pulmonary Arterial Hypertension Revealed by iPSC Modeling.
Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors.
Copy-number variation in BMPR2 is not associated with the pathogenesis of pulmonary arterial hypertension.
Correction of Nonsense BMPR2 and SMAD9 Mutations by Ataluren in Pulmonary Arterial Hypertension.
Correlation Between Single Nucleotide Polymorphisms of the rs664589 Locus in the Long-Chain Noncoding RNA Lung Adenocarcinoma Metastasis-Associated Gene 1, Hypertension, and Its Mechanism.
CORRIGENDUM: Alu-mediated nonallelic homologous and nonhomologous recombination in the BMPR2 gene in heritable pulmonary arterial hypertension.
Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension.
Cytokines trigger disruption of endothelium barrier function and p38 MAP kinase activation in BMPR2-silenced human lung microvascular endothelial cells.
Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension.
De novo mutations in the BMPR2 gene in patients with heritable pulmonary arterial hypertension.
Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2.
Deletion of the sequence encoding the tail domain of the bone morphogenetic protein type 2 receptor reveals a bone morphogenetic protein 7-specific gain of function.
Different forms of pulmonary hypertension in a family with clinical and genetic evidence for hereditary hemorrhagic teleangectasia type 2.
Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension.
Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension.
Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension.
Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension.
Early onset severe pulmonary arterial hypertension with 'two-hit' digenic mutations in both BMPR2 and KCNA5 genes.
Echocardiographic screening discloses increased values of pulmonary artery systolic pressure in 9 of 68 unselected patients affected with hereditary hemorrhagic telangiectasia.
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Emerging role of bone morphogenetic proteins in angiogenesis.
Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH.
Endoplasmic Reticulum Associated Protein Degradation (ERAD) in the Pathology of Diseases Related to TGF? Signaling Pathway: Future Therapeutic Perspectives.
Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling.
Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma.
Estrogen Receptor Alpha in Pulmonary Hypertension.
Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension.
EXPRESS: BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension.
Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells.
Extensive pulmonary sarcoid reaction in a patient with BMPR-2 associated idiopathic pulmonary arterial hypertension.
Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue.
Function of Adipose-Derived Mesenchymal Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension through miR-191 via Regulation of BMPR2.
Functional mutations in 5'UTR of the BMPR2 gene identified in Chinese families with pulmonary arterial hypertension.
Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: a meta-analysis.
Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary Arterial Hypertension suggests pathways relevant to disease penetrance.
Gene symbol: BMPR2. Disease: Pulmonary hypertension, primary.
Generation of pulmonary arterial hypertension patient-specific induced pluripotent stem cell lines from three unrelated patients with a heterozygous missense mutation in exon 12, a heterozygous in-frame deletion in exon 3 and a missense mutation in exon 11 of the BMPR2 gene.
Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension.
Genetic counselling in a national referral centre for pulmonary hypertension.
Genetic variants in the Polish population of patients with pulmonary arterial hypertension - sequencing of BMPR2, ALK1 and ENG genes.
Genetics of pulmonary hypertension: from bench to bedside.
Genotype-phenotype effects of Bmpr2 mutations on disease severity in mouse models of pulmonary hypertension.
Heart failure and pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia type 2.
Heart failure and pulmonary hypertension.
Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.
Heritable pulmonary hypertension: from bench to bedside.
High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension.
Hypermethylation of BMPR2 Promoter Occurs in the Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression.
Hypoxia regulates bone morphogenetic protein signaling through C-terminal-binding protein 1.
Hypoxia-Induced Pulmonary Hypertension in Different Mouse Strains - Relation to Transcriptome.
Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells.
Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II.
Identification of multiple ACVRL1 mutations in patients with pulmonary arterial hypertension by targeted exome capture.
Identities and frequencies of BMPR2 mutations in Chinese patients with idiopathic pulmonary arterial hypertension.
Idiopathic and heritable PAH perturb common molecular pathways, correlated with increased MSX1 expression.
Idiopathic pulmonary arterial hypertension associated with a novel frameshift mutation in the bone morphogenetic protein receptor II gene and enhanced bone morphogenetic protein signaling: A case report.
Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension.
Improved Survival of Patients with Pulmonary Arterial Hypertension with BMPR2 Mutations in the Last Decade.
Improvement of pulmonary arterial hypertension following medication and shunt closure in a BMPR2 mutation carrier with atrial septal defect.
In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and its Target Slug.
Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature.
Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity.
Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.
Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension.
Lack of circulating autoantibodies to bone morphogenetic protein receptor-II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension.
Loss-of BMPR2 is Associated With Abnormal DNA Repair in Pulmonary Arterial Hypertension.
Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension.
LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPAR? Activation.
Mate-pair sequencing identifies a cryptic BMPR2 mutation in hereditary pulmonary arterial hypertension.
Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle.
Methylation Analysis of the BMPR2 Gene Promoter Region in Patients With Pulmonary Arterial Hypertension.
Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions.
Missense Mutations of the BMPR1B (ALK6) Gene in Childhood Idiopathic Pulmonary Arterial Hypertension.
Modulation of Endothelial BMPR2 Activity by VEGFR3 in Pulmonary Arterial Hypertension.
Molecular Analysis of BMPR2, TBX4, and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families With Idiopathic and Hereditary Pulmonary Arterial Hypertension.
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension.
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension.
Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor.
Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension.
Mutations of NOTCH3 in childhood pulmonary arterial hypertension.
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.
N-linked glycosylation of the bone morphogenetic protein receptor type 2 (BMPR2) enhances ligand binding.
New pathogenic variant of BMPR2 in pulmonary arterial hypertension.
Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity.
Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report.
Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension.
Novel promoter and exon mutations of the BMPR2 gene in Chinese patients with pulmonary arterial hypertension.
Outcomes of Childhood Pulmonary Arterial Hypertension in BMPR2 and ALK1 Mutation Carriers.
Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.
Oxidative stress increases M1dG, a major peroxidation-derived DNA adduct, in mitochondrial DNA.
Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers.
Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele.
PERK inhibition attenuates vascular remodeling in pulmonary arterial hypertension caused by BMPR2 mutation.
Phenotypically-Silent Bone Morphogenetic Protein Receptor 2 (Bmpr2) Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing The Risk for Neointimal Transformation.
PPAR?-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension.
Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation.
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Proteomics of transformed lymphocytes from a family with familial pulmonary arterial hypertension.
Pulmonary arterial hypertension associated with hereditary spherocytosis and splenectomy in a patient with a mutation in the BMPR2 gene.
Pulmonary arterial hypertension preceding idiopathic pulmonary fibrosis in a BMPR2 mutation positive patient.
Pulmonary arterio-venous malformations in a patient with a novel mutation in exon 10 of the ACVRL1 gene.
Pulmonary capillary hemangiomatosis: a focus on the EIF2AK4 mutation in onset and pathogenesis.
Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?
Pulmonary hypertension in hereditary haemorrhagic telangiectasia.
Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations.
Pulmonary Vascular Platform Models the Effects of Flow and Pressure on Endothelial Dysfunction in BMPR2 Associated Pulmonary Arterial Hypertension.
Redox and Inflammatory Signaling, the Unfolded Protein Response, and the Pathogenesis of Pulmonary Hypertension.
Regulation of bone morphogenetic protein signalling in human pulmonary vascular development.
Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension.
Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension.
Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension.
Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations.
Right ventricular and pulmonary vascular reserve in asymptomatic BMPR2 mutation carriers.
RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension.
Role of SMURF1 ubiquitin ligase in BMP receptor trafficking and signaling.
Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation.
SCUBE1 Controls BMPR2-Relevant Pulmonary Endothelial Function: Implications for Diagnostic Marker Development in Pulmonary Arterial Hypertension.
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
Sequence Variants in BMPR2 and Genes Involved in the Serotonin and Nitric Oxide Pathways in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Relation to Clinical Parameters and Comparison with Left Heart Disease.
Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension.
Significance of BMPR2 mutations in pulmonary arterial hypertension.
Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension.
Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.
Somatic mosaicism in ACVRL1 with transmission to several offspring affected with severe pulmonary arterial hypertension.
Stoichiometric imbalance in the receptor complex contributes to dysfunctional BMPR-II mediated signalling in pulmonary arterial hypertension.
Structural basis for ALK2/BMPR2 receptor complex signaling through kinase domain oligomerization.
Structural consequences of BMPR2 kinase domain mutations causing pulmonary arterial hypertension.
SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling.
Subcellular mechanisms in pulmonary arterial hypertension: combinatorial modalities that inhibit anterograde trafficking and cause bone morphogenetic protein receptor type 2 mislocalization.
Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension.
Targeting BMPR2 Trafficking with Chaperones: An Important Step toward Precision Medicine in Pulmonary Arterial Hypertension.
Targeting translational read-through of premature termination mutations in BMPR2 with PTC124 for pulmonary arterial hypertension.
TGF-beta and BMPR-II pharmacology-implications for pulmonary vascular diseases.
TGF? and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension.
The BMPR2 missense mutation p.K230N and pulmonary arterial hypertension.
The Effects of Mercaptopurine on Pulmonary Vascular Resistance and BMPR2 Expression in Pulmonary Arterial Hypertension.
The Efficacy of a Genetic Analysis of the BMPR2 Gene in a Patient with Severe Pulmonary Arterial Hypertension and an Atrial Septal Defect Treated with Bilateral Lung Transplantation.
The features of rare pathogenic BMPR2 variants in pulmonary arterial hypertension: Comparison between patients and reference population.
The flavonoid quercetin reverses pulmonary hypertension in rats.
The P2-receptor-mediated Ca2+ signalosome of the human pulmonary endothelium - implications for pulmonary arterial hypertension.
The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension.
The transforming growth factor-?-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease.
Three novel BMPR2 mutations associated with advanced pulmonary arterial hypertension.
Towards Systems Biology of Pulmonary Hypertension.
Transforming growth factor beta/bone morphogenic protein signaling in pulmonary arterial hypertension: remodeling revisited.
Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood.
Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension.
What patients and their relatives think about testing for BMPR2.
Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension.
[Analysis of genetic mutation and modifier genes in pulmonary arterial hypertension]
[Bone morphogenetic protein type II receptor gene promoter mutation-142G > A in a patient with familial pulmonary arterial hypertension]
[Pulmonary hypertension: pathophysiology, genetics and functional genomics]
[Study of the BMPR2 gene in patients with pulmonary arterial hypertension]
Hypertension, Portal
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
[Pulmonary arterial hypertension]
[Pulmonary hypertension: from genetics to treatments]
Hypertension, Pulmonary
17?-Estradiol and estrogen receptor ? protect right ventricular function in pulmonary hypertension via BMPR2 and apelin.
5'UTR Repeat Polymorphisms of the BMPR2 gene in Children with Pulmonary Hypertension associated with Congenital Heart Disease.
A Case of Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia Related to an ACVRL1 Mutation.
A novel BMPR2 gene mutation associated with exercise-induced pulmonary hypertension in septal defects.
Adverse effects of BMPR2 suppression in macrophages in animal models of pulmonary hypertension.
Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension.
Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II.
BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia.
BMPR2 gene mutation in pulmonary arteriovenous malformation and pulmonary hypertension: a case report.
BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension.
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives.
Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
BMPR2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension.
BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension.
BMPR2 spruces up the endothelium in pulmonary hypertension.
BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.
Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.
CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
Characterization of the BMPR2 5'-untranslated region and a novel mutation in pulmonary hypertension.
Chloroquine Prevents Progression of Experimental Pulmonary Hypertension via Inhibition of Autophagy and Lysosomal Bmpr-II Degradation.
Chronic allergic inflammation causes vascular remodeling and pulmonary hypertension in BMPR2 hypomorph and wild-type mice.
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.
Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.
Combination use of sildenafil and simvastatin increases BMPR-II signal transduction in rats with monocrotaline-mediated pulmonary hypertension.
Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension.
Different forms of pulmonary hypertension in a family with clinical and genetic evidence for hereditary hemorrhagic teleangectasia type 2.
Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling.
Estrogen Metabolite 16?-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism.
Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells.
Extensive pulmonary sarcoid reaction in a patient with BMPR-2 associated idiopathic pulmonary arterial hypertension.
FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.
Gene symbol: BMPR2. Disease: Pulmonary hypertension, primary.
Genetic counselling in a national referral centre for pulmonary hypertension.
Genotype-phenotype effects of Bmpr2 mutations on disease severity in mouse models of pulmonary hypertension.
Heritable pulmonary hypertension: from bench to bedside.
HMGB1/TLR4 promotes hypoxic pulmonary hypertension via suppressing BMPR2 signaling.
Hyperoxia Synergizes with Mutant BMPR2 to Cause Metabolic Stress, Oxidant Injury, and Pulmonary Hypertension.
Hypoxia regulates bone morphogenetic protein signaling through C-terminal-binding protein 1.
Immunolocalisation of BMPR-II and TGF-ß type I and II receptors in primary plexogenic pulmonary hypertension.
Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature.
Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.
Interaction between bone morphogenetic proteins and endothelin-1 in human pulmonary artery smooth muscle.
Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3-microRNA Cluster 17/92 Pathway.
Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Longitudinal Analysis Casts Doubt on the Presence of Genetic Anticipation in Heritable Pulmonary Arterial Hypertension.
Modification of hemodynamic and immune responses to exposure with a weak antigen by the expression of a hypomorphic BMPR2 gene.
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
Mutations in BMPR2 are not present in patients with pulmonary hypertension associated with congenital diaphragmatic hernia.
Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease.
Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies.
Novel Advances in Modifying BMPR2 Signaling in PAH.
Novel insertional mutation in the bone morphogenetic protein receptor type II associated with sporadic primary pulmonary hypertension.
Paediatric pulmonary hypertension caused by an ACVRL1 mutation presenting as Ortner syndrome.
Pathobiology of pulmonary arterial hypertension.
Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers.
Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.
Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry.
Pulmonary arterial hypertension associated with hereditary spherocytosis and splenectomy in a patient with a mutation in the BMPR2 gene.
Pulmonary arterial hypertension-associated genetic variants in combined post-capillary and pre-capillary pulmonary hypertension: a case report.
Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?
Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle.
Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (rendu-osler disease).
Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension.
Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension.
Rho-kinase Inhibition Alleviates Pulmonary Hypertension in Transgenic Mice Expressing a Dominant-Negative Type II Bone Morphogenetic Protein Receptor Gene.
Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension.
Screening asymptomatic BMPR2 mutation carriers: a new frontier for pulmonary hypertension physicians?
Sequence Variants in BMPR2 and Genes Involved in the Serotonin and Nitric Oxide Pathways in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Relation to Clinical Parameters and Comparison with Left Heart Disease.
Sex hormone exposure and reproductive factors in pulmonary arterial hypertension: a case-control study.
Signaling molecules in nonfamilial pulmonary hypertension.
SMAD1 Deficiency in Either Endothelial or Smooth Muscle Cells Can Predispose Mice to Pulmonary Hypertension.
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.
SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling.
The ALK-1/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?
Towards Systems Biology of Pulmonary Hypertension.
Transcripts from a novel BMPR2 termination mutation escape nonsense mediated decay by downstream translation re-initiation: implications for treating pulmonary hypertension.
TWIST1 Drives Smooth Muscle Cell Proliferation in Pulmonary Hypertension via Loss of GATA-6 and BMPR2.
Hypertrophy, Right Ventricular
Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension.
Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2.
Elevated pulmonary arterial pressure in Zucker diabetic fatty rats.
Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Targeted gene delivery of BMPR-2 attenuates pulmonary hypertension.
Hypospadias
Molecular and toxicologic research in newborn hypospadiac male rats following in utero exposure to di-n-butyl phthalate (DBP).
Hypothyroidism
Deletion of 14.7?Mb 2q32.3q33.3 with a marfanoid phenotype and hypothyroidism.
Hepatocyte 'priming' and increase in transforming growth factor-beta1 mRNA expression are delayed in hypothyroid versus euthyroid rats during liver regeneration.
Idiopathic Pulmonary Fibrosis
Pulmonary arterial hypertension preceding idiopathic pulmonary fibrosis in a BMPR2 mutation positive patient.
Immunoglobulin G4-Related Disease
ALK-1 Positive Orbital Inflammatory Myofibroblastic Tumour (IMT) Associated with Prominent Numbers of IgG4 Plasma Cells-A Case Report.
Infarction, Middle Cerebral Artery
Ligustroflavone reduces necroptosis in rat brain after ischemic stroke through targeting RIPK1/RIPK3/MLKL pathway.
Infections
A cysteine-rich receptor-like protein kinase CaCKR5 modulates immune response against Ralstonia solanacearum infection in pepper.
A leucine-rich repeat receptor-like protein kinase (LRPKm1) gene is induced in Malus x domestica by Venturia inaequalis infection and salicylic acid treatment.
A RIPtide Protects Neurons from Infection.
Aberrant DNA methylation profile of hepatitis B virus infection.
An S-locus receptor-like kinase plays a role as a negative regulator in plant defense responses.
Bacterial meningitis: the role of transforming growth factor-Beta in innate immunity and secondary brain damage.
Bone morphogenetic protein 4 signaling regulates epithelial renewal in the urinary tract in response to uropathogenic infection.
Caspase-8 restricts natural killer cell accumulation during MCMV Infection.
Checkpoints in TNF-Induced Cell Death: Implications in Inflammation and Cancer.
Coxsackievirus A6 Induces Necroptosis for Viral Production.
DAI Another Way: Necroptotic Control of Viral Infection.
DAI Senses Influenza A Virus Genomic RNA and Activates RIPK3-Dependent Cell Death.
Dectin-1-induced RIPK1 and RIPK3 activation protects host against Candida albicans infection.
Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis.
EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation.
Genome-wide DNA methylation and RNA expression profiles identified RIPK3 as a differentially methylated gene in Chlamydia pneumoniae infection lung carcinoma patients in China.
HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells.
Human Rhinovirus 3C protease cleaves RIPK1, concurrent with caspase 8 activation.
Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II.
In vivo and in vitro phosphorylation of DNA-dependent RNA polymerase of Escherichia coli by bacteriophage-T7-induced protein kinase.
Inhibition of DAI-dependent necroptosis by the Z-DNA binding domain of the vaccinia virus innate immune evasion protein, E3.
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor.
Loss of periodontal ligament fibroblasts by RIPK3-MLKL-mediated necroptosis in the progress of chronic periodontitis.
Necroptosis Promotes Staphylococcus aureus Clearance by Inhibiting Excessive Inflammatory Signaling.
Newly Identified Function of Caspase-6 in ZBP1-mediated Innate Immune Responses, NLRP3 Inflammasome Activation, PANoptosis, and Host Defense.
Outcomes of RIP Kinase Signaling During Neuroinvasive Viral Infection.
p38(MAPK)/MK2-dependent phosphorylation controls cytotoxic RIPK1 signalling in inflammation and infection.
Programmed Necrosis in the Cross Talk of Cell Death and Inflammation.
Protein kinase of bacteriophage T7. 1. Purification.
Real-Time Induction of Macrophage Apoptosis, Pyroptosis, and Necroptosis by Enterococcus faecalis OG1RF and Two Root Canal Isolated Strains.
Receptor-interacting serine/threonine kinase 1- and 3-dependent inflammation induced in lungs of chicken infected with Pasteurella multocida.
Rhinovirus 3C protease suppresses apoptosis and triggers caspase-independent cell death.
RIPK1 and PGAM5 Control Leishmania Replication through Distinct Mechanisms.
RIPK1 Kinase-Dependent Death: A Symphony of Phosphorylation Events.
RIPK3 Activates MLKL-mediated Necroptosis and Inflammasome Signaling during Streptococcus Infection.
RIPK3 Facilitates Host Resistance to Oral Toxoplasma gondii Infection.
RIPK3 Is Largely Dispensable for RIG-I-Like Receptor- and Type I Interferon-Driven Transcriptional Responses to Influenza A Virus in Murine Fibroblasts.
Ripk3 licenced protection against microbial infection in the absence of Caspase1-11 inflammasome.
RIPK3 Promotes JEV Replication in Neurons via Downregulation of IFI44L.
RIPK3-Dependent Necroptosis Limits PRV Replication in PK-15 Cells.
RIPK3-Dependent Recruitment of Low-Inflammatory Myeloid Cells Does Not Protect from Systemic Salmonella Infection.
RIPK3/Fas-Associated Death Domain Axis Regulates Pulmonary Immunopathology to Cryptococcal Infection Independent of Necroptosis.
RIPK3: Beyond Necroptosis.
Role and Regulation of Nodal/Activin Receptor-Like Kinase 7 Signaling Pathway in the Control of Ovarian Follicular Atresia.
RSV Infection Promotes Necroptosis and HMGB1 Release by Airway Epithelial Cells.
Serine 25 phosphorylation inhibits RIPK1 kinase-dependent cell death in models of infection and inflammation.
Species-independent contribution of ZBP1/DAI/DLM-1-triggered necroptosis in host defense against HSV1.
Temporal and spatial assessment of defence responses in resistant and susceptible hop cultivars during infection with Verticillium nonalfalfae.
The latest information on the RIPK1 post-translational modifications and functions.
Therapeutic contribution of melatonin to the treatment of septic cardiomyopathy: A novel mechanism linking Ripk3-modified mitochondrial performance and endoplasmic reticulum function.
TNF-mediated alveolar macrophage necroptosis drives disease pathogenesis during respiratory syncytial virus infection.
Type I IFNs drive hematopoietic stem and progenitor cell collapse via impaired proliferation and increased RIPK1-dependent cell death during shock-like ehrlichial infection.
Viral dosing of influenza A infection reveals involvement of RIPK3 and FADD, but not MLKL.
Infertility
BMP-6 and SMAD4 gene expression is altered in cumulus cells from women with endometriosis-associated infertility.
Infertility, Female
BMPR2 is required for postimplantation uterine function and pregnancy maintenance.
Inflammatory Bowel Diseases
ABIN3 negatively regulates necroptosis-induced intestinal inflammation through recruiting A20 and restricting the ubiquitination of RIPK3 in inflammatory bowel disease.
Analyzing Necroptosis Using an RIPK1 Kinase Inactive Mouse Model of TNF Shock.
Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis.
Emerging views of mitophagy in immunity and autoimmune diseases.
How autophagy controls the intestinal epithelial barrier.
Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases.
Inhibition of RIPK3 Pathway Attenuates Intestinal Inflammation and Cell Death of Inflammatory Bowel Disease and Suppresses Necroptosis in Peripheral Mononuclear Cells of Ulcerative Colitis Patients.
Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation.
Publisher Correction: Death by inflammation: drug makers chase the master controller.
The scaffold-dependent function of RIPK1 in dendritic cells promotes injury-induced colitis.
Influenza, Human
Analysis of Cytokine- and Influenza A Virus-Driven RIPK3 Necrosome Formation.
RIPK3 Activates Parallel Pathways of MLKL-Driven Necroptosis and FADD-Mediated Apoptosis to Protect against Influenza A Virus.
RIPK3 interacts with MAVS to regulate type I IFN-mediated immunity to Influenza A virus infection.
RIPK3 Is Largely Dispensable for RIG-I-Like Receptor- and Type I Interferon-Driven Transcriptional Responses to Influenza A Virus in Murine Fibroblasts.
The Z?2 domain of ZBP1 is a molecular switch regulating influenza-induced PANoptosis and perinatal lethality during development.
Viral dosing of influenza A infection reveals involvement of RIPK3 and FADD, but not MLKL.
Viral strategies for triggering and manipulating mitophagy.
Insulin Resistance
PPAR? is a gatekeeper for extracellular matrix and vascular cell homeostasis: beneficial role in pulmonary hypertension and renal/cardiac/pulmonary fibrosis.
RIPK1 gene variants associate with obesity in humans and can be therapeutically silenced to reduce obesity in mice.
RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice.
The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance.
Intellectual Disability
The Fragile X Mental Retardation Protein Regulates RIPK1 and Colorectal Cancer Resistance to Necroptosis.
Intervertebral Disc Degeneration
Developing consistently reproducible intervertebral disc degeneration at rat caudal spine by using needle puncture.
High BMPR2 expression leads to enhanced SMAD1/5/8 signalling and GDF6 responsiveness in human adipose-derived stem cells: implications for stem cell therapies for intervertebral disc degeneration.
RIPK1 suppresses apoptosis mediated by TNF and caspase-3 in intervertebral discs.
Role of growth differentiation factor-5 and bone morphogenetic protein type II receptor in the development of lumbar intervertebral disc degeneration.
Intervertebral Disc Displacement
Transforming growth factor beta receptor induction in herniated intervertebral disc tissue: an immunohistochemical study.
Intestinal Neoplasms
TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway.
Intracranial Aneurysm
Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system.
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Endoglin is not a major susceptibility gene for intracranial aneurysm among Japanese.
Intracranial Hemorrhages
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Invasive Fungal Infections
RIPK3/Fas-Associated Death Domain Axis Regulates Pulmonary Immunopathology to Cryptococcal Infection Independent of Necroptosis.
Iron Overload
Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice.
ROS-Mediated Necroptosis Is Involved in Iron Overload-Induced Osteoblastic Cell Death.
Ischemic Stroke
Caspofungin Suppresses Brain Cell Necroptosis in Ischemic Stroke Rats via Up-Regulation of Pellino3.
Ligustroflavone reduces necroptosis in rat brain after ischemic stroke through targeting RIPK1/RIPK3/MLKL pathway.
Necrostatin-1 Prevents Necroptosis in Brains after Ischemic Stroke via Inhibition of RIPK1-Mediated RIPK3/MLKL Signaling.
Keloid
A novel truncated TGF-beta receptor II downregulates collagen synthesis and TGF-beta I secretion of keloid fibroblasts.
Blocking transforming growth factor-beta receptor signaling down-regulates transforming growth factor-beta1 autoproduction in keloid fibroblasts.
Complex epithelial-mesenchymal interactions modulate transforming growth factor-beta expression in keloid-derived cells.
Differential expression of transforming growth factor-beta receptors I and II and activation of Smad 3 in keloid fibroblasts.
Genetic susceptibility to keloid disease: transforming growth factor beta receptor gene polymorphisms are not associated with keloid disease.
SB-431542 inhibits TGF-beta-induced contraction of collagen gel by normal and keloid fibroblasts.
Keratosis, Actinic
Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
Keratosis, Seborrheic
Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma.
Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
Leiomyoma
Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells.
Leiomyosarcoma
ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder.
Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder.
Leukemia
Association between CASP7 and CASP14 genetic polymorphisms and the risk of childhood leukemia.
Differential expression of growth factors in irradiated mouse testes.
Expression of cyclin A and bone morphogenetic protein receptors and response to induction therapy in patients with acute leukemias.
Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease.
RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells.
Upregulation of Daxx mediates apoptosis in response to oxidative stress.
[Expression and significance of TGF-beta1, TbetaRII and c-myc in patients with acute leukemia]
[Identification of the isoform in type II receptor of transforming growth factor-beta in patients with acute leukemia and its clinical significance]
Leukemia, Lymphocytic, Chronic, B-Cell
The effect of FK506 on transforming growth factor beta signaling and apoptosis in chronic lymphocytic leukemia B cells.
Transforming growth factor-beta (TGF-beta)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-beta receptor.
Leukemia, Mast-Cell
Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease.
Leukemia, Myeloid, Acute
RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells.
RIPK3 Slams the Brake on Leukemogenesis.
[Correlation of NK cell RIPK1 with Prognosis of Acute Myeloid Leukemia Patients with FLT3-ITD Mutation].
Leukemia-Lymphoma, Adult T-Cell
Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL).
Leukodystrophy, Globoid Cell
Expression of Ripk1 and DAM genes correlates with severity and progression of Krabbe disease.
Lichen Planus, Oral
ALK1 expression in oral lichen planus: a possible relation to microvessel density.
Liver Cirrhosis
Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat.
Combination gene therapy of HGF and truncated type II TGF-beta receptor for rat liver cirrhosis after partial hepatectomy.
Hepatocyte-specific TAK1 deficiency drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and hepatocellular carcinoma.
Inhibition of ALK5 as a new approach to treat liver fibrotic diseases.
Kaempferol attenuates liver fibrosis by inhibiting activin receptor-like kinase 5.
Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10.
RIPK3 mRNA level acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma.
TGF-? Type I Receptor Kinase Inhibitor EW-7197 Suppresses Cholestatic Liver Fibrosis by Inhibiting HIF1?-Induced Epithelial Mesenchymal Transition.
Transforming growth factor betas and their receptors in human liver cirrhosis.
[Effects of antisense transforming growth factor beta receptor-I expressing plasmid on pig serum-induced rat liver fibrosis]
[Influence of interferon gamma treatment on expression of TGF-beta1 and its receptors in liver fibrosis of mice with schistosomiasis japonica]
Liver Cirrhosis, Biliary
Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice.
B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis.
Beta-glucosylceramide ameliorates liver inflammation in murine autoimmune cholangitis.
Emerging views of mitophagy in immunity and autoimmune diseases.
Inactivation of caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis.
Liver Diseases
Circulating Receptor-Interacting Protein Kinase 3 Are Increased in HBV Patients With Acute-on-Chronic Liver Failure and Are Associated With Clinical Outcome.
Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry.
Differential expression of transforming growth factor-beta and its receptors in hepatocytes and nonparenchymal cells of rat liver after CCl4 administration.
I?B kinase?/? control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell-death mediator receptor-interacting protein kinase 1.
Influence of Fat on Differential Receptor Interacting Serine/Threonine Protein Kinase 1 Activity Leading to Apoptotic Cell Death in Murine Liver Ischemia Reperfusion Injury Through Caspase 8.
JNK signaling prevents biliary cyst formation through a CASPASE-8-dependent function of RIPK1 during aging.
Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis.
RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury.
RIPK1 protects from TNF-?-mediated liver damage during hepatitis.
RIPK1 targeting protects against obesity and atherosclerosis.
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis.
The Receptor Interacting Protein Kinases in the Liver.
The role of RIPK3 in liver mitochondria bioenergetics and function.
Liver Neoplasms
Effects of siRNA targeting BMPR-II on the biological activities of human liver cancer cells and its mechanism.
RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer.
Loeys-Dietz Syndrome
A case of near total aortic replacement in an adolescent with loeys-dietz syndrome.
A Japanese family of typical Loeys-Dietz syndrome with a TGFBR2 mutation.
Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation.
Generation of an induced pluripotent stem cell line from a Loeys-Dietz syndrome patient with transforming growth factor-beta receptor-2 gene mutation.
Germline TGF-beta receptor mutations and skeletal fragility: a report on two patients with Loeys-Dietz syndrome.
High prevalence of vertebral artery tortuosity of Loeys-Dietz syndrome in comparison with Marfan syndrome.
Loeys-Dietz syndrome in pregnancy: a case description and report of a novel mutation.
Musculoskeletal findings of Loeys-Dietz syndrome.
Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity.
Surgical Experience With Aggressive Aortic Pathologic Process in Loeys-Dietz Syndrome.
Surgical Outcome and Histological Differences between Individuals with TGFBR1 and TGFBR2 Mutations in Loeys-Dietz Syndrome.
The differences in surgical long-term outcomes between Marfan syndrome and Loeys-Dietz syndrome.
[Loeys-Dietz syndrome with acute myeloid leukemia]
[Marfan-like aortic aneurysm syndrome; A surgical experience with Loeys-Dietz syndrome]
Lung Diseases
Necroptosis: a crucial pathogenic mediator of human disease.
Lung Injury
Deficiency of receptor-interacting protein kinase 3 (RIPK3) attenuates inflammation and organ injury in neonatal sepsis.
Expression of transforming growth factor-beta type I and type II receptors is altered in rat lungs undergoing bleomycin-induced pulmonary fibrosis.
Inhibition of activin receptor-like kinase 5 induces matrix metallopeptidase 9 expression and aggravates lipopolysaccharide-induced pulmonary injury in mice.
Receptor-interacting serine/threonine kinase 1- and 3-dependent inflammation induced in lungs of chicken infected with Pasteurella multocida.
TNF-mediated alveolar macrophage necroptosis drives disease pathogenesis during respiratory syncytial virus infection.
TREM-1 Attenuates RIPK3 Mediated Necroptosis in Hyperoxia Induced Lung Injury in Neonatal Mice.
Lung Neoplasms
Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer.
Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation.
CNOT3 contributes to cisplatin resistance in lung cancer through inhibiting RIPK3 expression.
Expression and autoregulation of transforming growth factor beta receptor mRNA in small-cell lung cancer cell lines.
Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines.
Genome-wide DNA methylation and RNA expression profiles identified RIPK3 as a differentially methylated gene in Chlamydia pneumoniae infection lung carcinoma patients in China.
Microarray analysis of promoter methylation in lung cancers.
MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma.
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Prognostic Significance of CHIP and RIPK3 in Non-Small Cell Lung Cancer.
Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells.
Single-nucleotide polymorphism rs17548629 in RIPK1 gene may be associated with lung cancer in a young and middle-aged Han Chinese population.
TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.
Lupus Erythematosus, Systemic
Emerging views of mitophagy in immunity and autoimmune diseases.
Lupus Nephritis
Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis.
Regulated necrosis-related molecule mRNA expression in humans and mice and in murine acute tissue injury and systemic autoimmunity leading to progressive organ damage, and progressive fibrosis.
Lymphadenopathy
A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1.
The Pseudokinase MLKL and the Kinase RIPK3 Have Distinct Roles in Autoimmune Disease Caused by Loss of Death-Receptor-Induced Apoptosis.
Lymphatic Metastasis
Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice.
Receptor-Interacting Protein Kinase 1 Promotes Cholangiocarcinoma Proliferation And Lymphangiogenesis Through The Activation Protein 1 Pathway.
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
RIPK3 Suppresses the Progression of Spontaneous Intestinal Tumorigenesis.
The Expression of Activin Receptor-Like Kinase 1 among Patients with Head and Neck Cancer.
Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer.
[Functional significance of TGF-beta1 signal transduction pathway in oral squamous cell carcinoma]
Lymphedema
EW-7197, a Transforming Growth Factor-Beta Type I Receptor Kinase Inhibitor, Ameliorates Acquired Lymphedema in a Mouse Tail Model.
Lymphoma
24(S)-Hydroxycholesterol induces RIPK1-dependent but MLKL-independent cell death in the absence of caspase-8.
A Case of Secondary Sclerosing Cholangitis in the setting of Non-Hodgkin's Lymphoma.
A Comparative Study of Inflammatory Myofibroblastic Tumors and Tumefactive IgG4-related Inflammatory Lesions: the Relevance of IgG4 Plasma Cells.
A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma.
Aggressive presentation of breast implant-associated ALK-1 negative anaplastic large cell lymphoma with bilateral axillary lymph node involvement.
Altered regulation of cyclic AMP-dependent protein kinase in a mouse lymphoma cell line.
Anaplastic large cell lymphoma associated with a breast implant capsule: a case report and review of the literature.
Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology.
Anaplastic lymphoma of the cervical esophagus presenting as a tracheoesophageal fistula.
Association of Marek's Disease induced immunosuppression with activation of a novel regulatory T cells in chickens.
Bone marrow involvement in systemic alk+ anaplastic large cell lymphoma: morphological resemblance with hodgkin s lymphoma.
Case report: A unique pediatric case of a primary CD8 expressing ALK-1 positive anaplastic large cell lymphoma of skeletal muscle.
CD5- and CD23-positive splenic diffuse large B-cell lymphoma with very low CD20 expression.
Clinical Significance of ALK-1 Gene Abnormalities in Diffuse Large Cell Lymphoma.
Cutaneous Anaplastic Large-Cell Lymphoma Should be Evaluated for Systemic Involvement Regardless of ALK-1 Status: Case Reports and Review of Literature.
Decreased expression of TGF-beta type 2 receptor in primary B-cell lymphomas of the stomach.
Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma.
Fine needle aspiration cytology of ALK 1(-), CD 30(+) anaplastic large cell lymphoma post renal transplantation: A case report and literature review.
Granulomatous slack skin mycosis fungoides developing simultaneously with sarcoid-like lesions in a patient with repeated anabolic injections in the past?
Histiocytic sarcoma of the cavernous sinus: case report and literature review.
Identification of a novel common proviral integration site, flit-1, in feline leukemia virus induced thymic lymphoma.
Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells.
MSH2-deficient murine lymphomas harbor insertion/deletion mutations in the transforming growth factor beta receptor type 2 gene and display low not high frequency microsatellite instability.
Multi-lineage interrogation of the performance characteristics of a split-signal fluorescence in situ hybridization probe for anaplastic lymphoma kinase gene rearrangements: a study of 101 cases characterized by immunohistomorphology on fixed archival tissue.
Novel ALK inhibitors in clinical use and development.
Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression.
Primary hepatic Epstein-Barr virus-associated CD30-positive peripheral T-cell lymphoma of cytotoxic phenotype.
Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand.
Subunit interaction in cyclic AMP-dependent protein kinase of mutant lymphoma cells.
Transforming growth factor-beta1 effects on endothelial monolayer permeability involve focal adhesion kinase/Src.
[ALK-1 positive anaplastic large cell lymphoma of the lung. Report of a pediatric case]
Lymphoma, B-Cell
Anaplastic Lymphoma Kinase Immunocytochemistry in Fine Needle Aspiration Diagnosis of Anaplastic Large-cell Lymphoma.
BMPRII deficiency impairs apoptosis via the BMPRII-ALK1-BclX-mediated pathway in pulmonary arterial hypertension.
Effects of prostaglandin F2? (PGF2?) on cell-death pathways in the bovine corpus luteum (CL).
Resistance to TGF-beta 1 correlates with aberrant expression of TGF-beta receptor II in human B-cell lymphoma cell lines.
[Marfan syndrome complicated with CD5+ CD10+ diffuse large B-cell lymphoma]
Lymphoma, Large B-Cell, Diffuse
Anaplastic Lymphoma Kinase Immunocytochemistry in Fine Needle Aspiration Diagnosis of Anaplastic Large-cell Lymphoma.
Clinical Significance of ALK-1 Gene Abnormalities in Diffuse Large Cell Lymphoma.
Lymphoma, Large-Cell, Anaplastic
Aggressive presentation of breast implant-associated ALK-1 negative anaplastic large cell lymphoma with bilateral axillary lymph node involvement.
Anaplastic large cell lymphoma associated with a breast implant capsule: a case report and review of the literature.
Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology.
Bone marrow involvement in systemic alk+ anaplastic large cell lymphoma: morphological resemblance with hodgkin s lymphoma.
Case report: A unique pediatric case of a primary CD8 expressing ALK-1 positive anaplastic large cell lymphoma of skeletal muscle.
Cutaneous Anaplastic Large-Cell Lymphoma Should be Evaluated for Systemic Involvement Regardless of ALK-1 Status: Case Reports and Review of Literature.
Histiocytic sarcoma of the cavernous sinus: case report and literature review.
Novel ALK inhibitors in clinical use and development.
Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression.
[ALK-1 positive anaplastic large cell lymphoma of the lung. Report of a pediatric case]
Lymphoma, T-Cell
Loss of receptors for transforming growth factor beta in human T-cell malignancies.
Lymphoma, T-Cell, Cutaneous
A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma.
Lymphoproliferative Disorders
EMA and ALK-1 Immunostaining in Cutaneous CD30+ Lymphoproliferative Disorders.
Marfan Syndrome
Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation.
Heterozygous TGFBR2 mutations in Marfan syndrome.
Phenotypic heterogeneity of Marfan-like connective tissue disorders associated with mutations in the transforming growth factor-beta receptor genes.
Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity.
The differences in surgical long-term outcomes between Marfan syndrome and Loeys-Dietz syndrome.
Massive Hepatic Necrosis
Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis.
Measles
Viral strategies for triggering and manipulating mitophagy.
Melanoma
Absence of RIPK3 predicts necroptosis resistance in malignant melanoma.
ACTN4 regulates the stability of RIPK1 in melanoma.
Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.
Dabrafenib, an inhibitor of RIP3 kinase-dependent necroptosis, reduces ischemic brain injury.
Divergence(s) in nodal signaling between aggressive melanoma and embryonic stem cells.
Emerging views of mitophagy in immunity and autoimmune diseases.
In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours.
RIPK1 regulates survival of human melanoma cells upon endoplasmic reticulum stress through autophagy.
TAK1 suppresses RIPK1-dependent cell death and is associated with disease progression in melanoma.
The double life of RIPK1.
Memory Disorders
RIPK1 mediates a disease-associated microglial response in Alzheimer's disease.
Meningioma
Transforming growth factor-beta and transforming growth factor beta-receptor expression in human meningioma cells.
Meningitis
Bacterial meningitis: the role of transforming growth factor-Beta in innate immunity and secondary brain damage.
Mesothelioma
A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
Mesothelioma, Malignant
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma.
Metabolic Diseases
Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2.
RIPK1 targeting protects against obesity and atherosclerosis.
Mixed Connective Tissue Disease
Lack of circulating autoantibodies to bone morphogenetic protein receptor-II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension.
Mucocutaneous Lymph Node Syndrome
[Association of single nucleotide polymorphism in TGFBR2 gene with Kawasaki disease and coronary artery lesions].
Multiple Myeloma
Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk.
Multiple Sclerosis
RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosis.
Muscle Spasticity
Hereditary spastic paraplegia-causing mutations in atlastin-1 interfere with BMPRII trafficking.
Myocardial Infarction
Correction to: MicroRNA-325-3p protects the heart after myocardial infarction by inhibiting RIPK3 and programmed necrosis in mice.
Endothelial cells are activated during hypoxia via endoglin/ALK-1/SMAD1/5 signaling in vivo and in vitro.
MicroRNA-325-3p protects the heart after myocardial infarction by inhibiting RIPK3 and programmed necrosis in mice.
Primidone blocks RIPK1-driven cell death and inflammation.
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
RIPK3 Induces Cardiomyocyte Necroptosis via Inhibition of AMPK-Parkin-Mitophagy in Cardiac Remodelling after Myocardial Infarction.
Ripk3 mediates cardiomyocyte necrosis through targeting mitochondria and the JNK-Bnip3 pathway under hypoxia-reoxygenation injury.
Serum levels of RIPK3 and troponin I as potential biomarkers for predicting impaired left ventricular function in patients with myocardial infarction with ST segment elevation and normal troponin I levels prior percutaneous coronary intervention.
Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction.
The long noncoding RNA NRF regulates programmed necrosis and myocardial injury during ischemia and reperfusion by targeting miR-873.
Myocardial Ischemia
Sevoflurane postconditioning reduces myocardial ischemia reperfusion injury-induced necroptosis by up-regulation of OGT-mediated O-GlcNAcylated RIPK3.
Myositis Ossificans
A Novel Factor, Tmem176b, Induced by Activin-like Kinase 2 Signal Promotes the Differentiation of Myoblasts into Osteoblasts.
A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.
A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.
ALK2 R206H Mutation Linked to Fibrodysplasia Ossificans Progressiva Confers Constitutive Activity to the BMP Type I Receptor and Sensitizes Mesenchymal Cells to BMP-Induced Osteoblast Differentiation and Bone Formation.
Augmented BMP signaling commits cranial neural crest cells to a chondrogenic fate by suppressing autophagic ?-catenin degradation.
In vitro Analyses of the Dysregulated R206H ALK2 Kinase-FKBP12 Interaction Associated with Heterotopic Ossification in FOP.
Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.
Measurement of constitutive activity of BMP type I receptors.
Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.
Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches.
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
The role of the 3'UTR region in the regulation of the ACVR1/Alk-2 gene expression.
The unique activity of bone morphogenetic proteins in bone: a critical role of the Smad signaling pathway.
Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.
When bone becomes your enemy: fibrodysplasia ossificans progressiva.
Neonatal Sepsis
Deficiency of receptor-interacting protein kinase 3 (RIPK3) attenuates inflammation and organ injury in neonatal sepsis.
Neoplasm Metastasis
Activin-like kinase 5 (ALK5) inactivation in the mouse uterus results in metastatic endometrial carcinoma.
ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells.
ALK7 Promotes Vascular Smooth Muscle Cells Phenotypic Modulation by Negative Regulating PPAR? Expression.
Analysis of genomics and immune infiltration patterns of epithelial-mesenchymal transition related to metastatic breast cancer to bone.
BMP signaling pathways affect differently migration and invasion of esophageal squamous cancer cells.
BMPR2 and HIF1-
BMPR2 expression level is correlated with low immune infiltration and predicts metastasis and poor survival in osteosarcoma.
BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation.
BMPR2 promotes invasion and metastasis via the RhoA-ROCK-LIMK2 pathway in human osteosarcoma cells.
Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone.
Breast Cancer Special Feature: Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators.
C23 protein meditates bone morphogenetic protein-2-mediated EMT via up-regulation of Erk1/2 and Akt in gastric cancer.
Clinicopathological Study of 18 Cases of Inflammatory Myofibroblastic Tumors with Reference to ALK-1 Expression: 5-Year Experience in a Tertiary Care Center.
Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice.
Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
Expression of bone morphogenetic proteins and receptors in sarcomas.
Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta.
Identification of miR-135b as a novel regulator of TGF? pathway in gastric cancer.
Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.
Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo.
Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor.
Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.
Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness.
Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level.
Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases.
Nucleolar and Spindle Associated Protein 1 (NUSAP1) Promotes Bladder Cancer Progression Through the TGF-? Signaling Pathway.
p130Cas is required for mammary tumor growth and transforming growth factor-{beta} (TGF-{beta})-mediated metastasis through regulation of Smad2/3 activity.
Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.
Receptor-Interacting Protein Kinase 1 Promotes Cholangiocarcinoma Proliferation And Lymphangiogenesis Through The Activation Protein 1 Pathway.
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
Reduced transforming growth factor-beta receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis.
Reduction of invasive potential in K-ras-transformed thyroid cells by restoring of TGF-beta pathway.
RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis.
Soluble transforming growth factor beta type II receptor attenuates TGF-beta1 activity in human colorectal cancer LoVo cells.
Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis.
TAK1 regulates endothelial cell necroptosis and tumor metastasis.
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer.
The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice.
The Expression of Activin Receptor-Like Kinase 1 among Patients with Head and Neck Cancer.
The RING finger protein11 binds to Smad4 and enhances Smad4-dependant TGF-beta signalling.
The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma.
The type III TGF-beta receptor suppresses breast cancer progression.
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Transforming growth factor beta type I receptor acts as a potent tumor suppressor in rat bladder carcinoma.
Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer.
Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis.
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer.
[Functional significance of TGF-beta1 signal transduction pathway in oral squamous cell carcinoma]
Neoplasms
24(S)-Hydroxycholesterol induces RIPK1-dependent but MLKL-independent cell death in the absence of caspase-8.
25 years of research put RIPK1 in the clinic.
3-O-acetylrubianol C (3AR-C) induces RIPK1-dependent programmed cell death by selective inhibition of IKK?.
8-Geranylumbelliferone isolated from Paramignya trimera triggers RIPK1/RIPK3-dependent programmed cell death upon TNFR1 ligation.
?Np63?-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells.
A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).
A Comparative Study of Inflammatory Myofibroblastic Tumors and Tumefactive IgG4-related Inflammatory Lesions: the Relevance of IgG4 Plasma Cells.
A critical role for transcription factor Smad4 in T cell function that is independent of transforming growth factor ? receptor signaling.
A cytosolic heat shock protein 90 and co-chaperone p23 complex activates RIPK3/MLKL during necroptosis of endothelial cells in acute respiratory distress syndrome.
A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma.
A dual role for Caspase8 and NF-?B interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival.
A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression.
A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors.
A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.
A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207.
A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.
A RIPK3-PGE2 Circuit Mediates Myeloid-Derived Suppressor Cell-Potentiated Colorectal Carcinogenesis.
A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers.
Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.
Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sézary syndrome identified by gene expression analysis.
Aberrant methylation inactivates transforming growth factor Beta receptor I in head and neck squamous cell carcinoma.
Aberrant transforming growth factor-beta signaling in azoxymethane-induced mouse colon tumors.
Absence of expression of transforming growth factor-beta type II receptor is associated with an aggressive growth pattern in a murine renal carcinoma cell line, Renca.
Absence of RIPK3 predicts necroptosis resistance in malignant melanoma.
Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis.
Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer.
Activated human B cells induce inflammatory fibroblasts with cartilage-destructive properties and become functionally suppressed in return.
Activation of necroptosis in multiple sclerosis.
Activin receptor-like kinase 1 is associated with immune cell infiltration and regulates CLEC14A transcription in cancer.
Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.
Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis.
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.
ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer.
ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder.
ALK-1 Positive Orbital Inflammatory Myofibroblastic Tumour (IMT) Associated with Prominent Numbers of IgG4 Plasma Cells-A Case Report.
ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract.
Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma.
Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic human gastrointestinal cancer.
Analysis of TGF-beta type I receptor for mutations and polymorphisms in head and neck cancers.
Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.
Anaplastic large cell lymphoma (ALCL) presenting as primary bone and soft tissue sarcoma--a study of 12 cases.
Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies.
Antioxidant and food additive BHA prevents TNF cytotoxicity by acting as a direct RIPK1 inhibitor.
Antitumor activity of ALK1 in pancreatic carcinoma cells.
Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Atg14 protects the intestinal epithelium from TNF-triggered villus atrophy.
Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer.
Attenuated type II TGF-beta receptor signalling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination.
Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation.
Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells.
Biology of transforming growth factor beta in hepatocarcinogenesis.
Blastic plasmacytoid dendritic cell neoplasm presenting as fever with diffuse cutaneous nodules.
Blockade of transforming growth factor-beta (TGF?) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line.
BMP signaling pathways affect differently migration and invasion of esophageal squamous cancer cells.
BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells.
BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer.
BMPR2 and HIF1-
BMPR2 expression level is correlated with low immune infiltration and predicts metastasis and poor survival in osteosarcoma.
BMPR2 inhibition induced apoptosis and autophagy via destabilization of XIAP in human chondrosarcoma cells.
BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation.
BMPR2 promotes fatty acid oxidation and protects white adipocytes from cell death in mice.
BMPR2-pSMAD1/5 signaling pathway regulates RUNX2 expression and impacts the progression of dedifferentiated chondrosarcoma.
BMPRII is a direct target of miR-21.
Bone morphogenetic protein 9 (BMP9) and BMP10 enhance tumor necrosis factor-?-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2.
Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression.
BRAF and AXL oncogenes drive RIPK3 expression loss in cancer.
Breast Cancer Special Feature: Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators.
c-Jun N-terminal kinases differentially regulate TNF- and TLRs-mediated necroptosis through their kinase-dependent and -independent activities.
Ca
Casein kinase-1?1 and 3 stimulate tumor necrosis factor-induced necroptosis through RIPK3.
Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening.
Characterization of novel transforming growth factor-beta type I receptors found in malignant pleural effusion tumor cells.
Characterization of protein tyrosine kinase activity in murine Leydig tumor cells.
Chlamydia trachomatis fails to protect its growth niche against pro-apoptotic insults.
Clear Cell Primary Cutaneous Anaplastic Large Cell Lymphoma.
Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2.
Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer.
Clinicopathological Study of 18 Cases of Inflammatory Myofibroblastic Tumors with Reference to ALK-1 Expression: 5-Year Experience in a Tertiary Care Center.
Collision Tumor Composed of an Inflammatory Myofibroblastic Tumor and Adenocarcinoma of the Colon: a Rare Entity.
Colonic inflammatory myofibroblastic tumours: an institutional review.
Computational analyses of interactions between ALK-5 and bioactive ligands: insights for the design of potential anticancer agents.
Connective tissue growth factor gene expression alters tumor progression in esophageal cancer.
Conversion of normal human oral keratinocytes to tumorigenic cells is associated with the acquisition of resistance to TGF-beta.
Coordinated functions of E-cadherin and transforming growth factor beta receptor II in vitro and in vivo.
Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis.
Cytomorphology of ALK+ anaplastic large cell lymphoma displaying spindle cells mimicking a sarcomatous tumor: Report of a case.
Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients.
Decreased RIPK1 expression in chondrocytes alleviates osteoarthritis via the TRIF/MyD88-RIPK1-TRAF2 negative feedback loop.
Dedifferentiated Liposarcoma With Inflammatory Myofibroblastic Tumor-like Features.
Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Dehydroleucodine Induces a TP73-dependent Transcriptional Regulation of Multiple Cell Death Target Genes in Human Glioblastoma Cells.
Deletion of one adenine base within the polyadenine tract of transforming growth factor-beta receptor type II in human MDA-MB-231 breast cancer cell line.
Deregulated bone morphogenetic proteins and their receptors are associated with disease progression of gastric cancer.
DIABLO/SMAC mimetics selectively kill HIV-1-infected resting memory CD4+ T cells: a potential role in a cure strategy for HIV-1 infection.
Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: Implications in the modulation of cell proliferation.
Differential expression of and responsiveness to transforming growth factor-beta (TGF-beta) isoforms in hormone-dependent and independent lines of mouse mammary tumors.
Differential expression of growth factors in irradiated mouse testes.
Differentiation of malignant oral rat keratinocytes reflects changes in EGF and TGF-beta receptor expression but not growth factor dependence.
Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-? type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
Downregulation of bone morphogenetic protein receptor 2 promotes the development of neuroblastoma.
Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Emerging views of mitophagy in immunity and autoimmune diseases.
Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers.
Endoglin: Beyond the Endothelium.
Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer.
Epithelial HMGB1 Delays Skin Wound Healing and Drives Tumor Initiation by Priming Neutrophils for NET Formation.
EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation.
EW-7197, an oral transforming growth factor ? type I receptor kinase inhibitor, for preventing peritoneal adhesion formation in a rat model.
Expression and genetic polymorphism of necroptosis related protein RIPK1 is correlated with severe hepatic ischemia-reperfusion injury and prognosis after hepatectomy in hepatocellular carcinoma patients.
Expression of a new type high molecular weight receptor (type V receptor) of transforming growth factor beta in normal and transformed cells.
Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy.
Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues.
Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients.
Expression of bone morphogenetic protein-6 and bone morphogenetic protein receptors in myoepithelial cells of canine mammary gland tumors.
Expression of bone morphogenetic proteins and receptors in sarcomas.
Expression of cytokine receptors on follicular dendritic cells.
Expression of key regulatory genes in necroptosis and its effect on the prognosis in non-small cell lung cancer.
Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-beta.
Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
Expression of TGF-beta type II receptor antisense RNA impairs TGF-beta signaling in vitro and promotes mammary gland differentiation in vivo.
Expression of TGF-beta1, TbetaRII and Smad4 in colorectal carcinoma.
Expression of transforming growth factor beta and transforming growth factor beta receptors on AIDS-associated Kaposi's sarcoma.
Expression of transforming growth factor beta type II receptors in head and neck squamous cell carcinoma.
Expression of transforming growth factor beta1 and its type II receptor in mouse colon tumors induced by azoxymethane.
Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment.
Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.
Expression of Transforming Growth Factor-beta Receptors and Related Cell-Cycle Components in Transitional-Cell Carcinoma of the Bladder.
Expression of transforming growth factor-beta1 and transforming growth factor-beta receptors in hepatocellular carcinoma and dysplastic nodules.
Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy.
FADD and Caspase-8 Regulate Gut Homeostasis and Inflammation by Controlling MLKL- and GSDMD-Mediated Death of Intestinal Epithelial Cells.
Featured Article: microRNA-125a in pulmonary hypertension: Regulator of a proliferative phenotype of endothelial cells.
Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
FKBP12 mediates necroptosis by initiating RIPK1-RIPK3-MLKL signal transduction in response to TNF receptor 1 ligation.
Function of the type V transforming growth factor beta receptor in transforming growth factor beta-induced growth inhibition of mink lung epithelial cells.
Furosine, a Maillard Reaction Product, Triggers Necroptosis in Hepatocytes by Regulating the RIPK1/RIPK3/MLKL Pathway.
G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program.
Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF-beta type II receptor, IGFII receptor, and BAX genes.
Gene expression of cytokine receptors in HL60 cells exposed to a 50 Hz magnetic field.
Gene expression of transforming growth factor beta receptors I and II in non-small-cell lung tumors.
Genetic alterations in the transforming growth factor receptor complex in sporadic endometrial carcinoma.
Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis.
Genetic modifiers interact with maternal determinants in vascular development of Tgfb1(-/-) mice.
Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer.
Genetic variation in bone morphogenetic proteins and breast cancer risk in hispanic and non-hispanic white women: The breast cancer health disparities study.
Genipin ameliorates diet-induced obesity via promoting lipid mobilization and browning of white adipose tissue in rats.
Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta.
Growth inhibition induced by transforming growth factor-beta1 in human oral squamous cell carcinoma.
Growth inhibition of a human lymphoma cell line: induction of a transforming growth factor-beta-mediated autocrine negative loop by phorbol myristate acetate.
Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis.
Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
Hepatocyte Necroptosis Induced by Ischemic Acute Kidney Injury in Rats.
Hepatocyte-specific TAK1 deficiency drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and hepatocellular carcinoma.
High-grade myofibroblastic sarcoma in the liver: A case report.
Histiocytic sarcoma of the cavernous sinus: case report and literature review.
Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth.
How autophagy controls the intestinal epithelial barrier.
Human cut-like repressor protein binds TGFbeta type II receptor gene promoter.
Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway.
Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein.
Hypoxia upregulates adhesion ability to peritoneum through a transforming growth factor-beta-dependent mechanism in diffuse-type gastric cancer cells.
I?B kinase?/? control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell-death mediator receptor-interacting protein kinase 1.
IAP antagonists sensitize murine osteosarcoma cells to killing by TNF?.
Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II.
Identification of a novel common proviral integration site, flit-1, in feline leukemia virus induced thymic lymphoma.
Identification of miR-135b as a novel regulator of TGF? pathway in gastric cancer.
Identification of PCTA, a TGIF antagonist that promotes PML function in TGF-beta signalling.
IFN-gamma and TNF-alpha inhibit expression of TGF-beta-1, its receptors TBETAR-I and TBETAR-II in the corpus luteum of PMSG/hCG treated rhesus monkey.
IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link?
IL-6 signaling promotes tumor growth in colorectal cancer.
Immunocytochemical features of lens after cataract tissue--signalling molecules (growth factors, cytokines, other signalling molecules), cytoskeleton proteins, cellular and extracellular matrix proteins.
Immunohistochemical analysis of embryonal sarcoma of the liver.
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling.
In Systemic Sclerosis, a Unique Long Non Coding RNA Regulates Genes and Pathways Involved in the Three Main Features of the Disease (Vasculopathy, Fibrosis and Autoimmunity) and in Carcinogenesis.
In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours.
Increased expression of TGF-beta1 reduces tumor growth of human U-87 Glioblastoma Cells in vivo.
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases.
Increased TGFbeta type II receptor expression suppresses the malignant phenotype and induces differentiation of human neuroblastoma cells.
Inducing regulated necrosis and shifting macrophage polarization with anti-EMMPRIN antibody (161-pAb) and complement factors.
Inflammatory myofibroblastic tumor of the trachea with concomitant granulomatous lymph node lesions.
Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.
Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors.
Inhibition of bone morphogenetic protein receptor 2 suppresses pancreatic ductal adenocarcinoma growth by regulating GRB2/PI3K/AKT axis.
Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.
Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma.
Int7G24A variant of transforming growth factor-beta receptor 1 is associated with osteosarcoma susceptibility in a Chinese population.
Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators.
Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma.
Interferon-? induces the cell surface exposure of phosphatidylserine by activating the protein MLKL in the absence of caspase-8 activity.
Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity.
Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension.
Key roles of necroptotic factors in promoting tumor growth.
Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis.
Lack of frameshift mutations at coding mononucleotide repeats in hepatocellular carcinoma in Japanese patients.
Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of 11C-Labeled ALK2 Inhibitors.
Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling.
Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma.
Loss of growth regulation by transforming growth factor-beta (TGF-beta) in human cancers: studies on endometrial carcinoma.
Loss of receptors for transforming growth factor beta in human T-cell malignancies.
Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
Low-grade abdominopelvic sarcoma with myofibroblastic features (low-grade myofibroblastic sarcoma): clinicopathological, immunohistochemical, molecular genetic and ultrastructural study of two cases with literature review.
Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma.
Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness.
Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES.
Malignant cells, directors of the malignant process: role of transforming growth factor-beta.
Microarray analysis of promoter methylation in lung cancers.
MicroRNA-381-3p Functions as a Dual Suppressor of Apoptosis and Necroptosis and Promotes Proliferation of Renal Cancer Cells.
MicroRNA100 inhibits self-renewal of breast cancer stem-like cells and breast tumor development.
Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level.
Microsatellite instability in young patients with colorectal cancer.
Microsatellite instability, prognosis and metastasis in gastric cancers from a low-risk population.
miR-100-3p inhibits cell proliferation and induces apoptosis in human gastric cancer through targeting to BMPR2.
MLKL in cancer: more than a necroptosis regulator.
Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms.
Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis.
More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.
MSH2-deficient murine lymphomas harbor insertion/deletion mutations in the transforming growth factor beta receptor type 2 gene and display low not high frequency microsatellite instability.
MUC13 protects colorectal cancer cells from death by activating the NF-?B pathway and is a potential therapeutic target.
Multi-lineage interrogation of the performance characteristics of a split-signal fluorescence in situ hybridization probe for anaplastic lymphoma kinase gene rearrangements: a study of 101 cases characterized by immunohistomorphology on fixed archival tissue.
Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck.
Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma.
Mutational analysis of transforming growth factor-beta receptor type II and Smad3 tumor suppressor genes in prolactinomas.
Mutations of the transforming growth factor beta type II receptor gene and microsatellite instability in gastric cancer.
Myeloid tumor necrosis factor and heme oxygenase-1 regulate the progression of colorectal liver metastases during hepatic ischemia-reperfusion.
N-end rule pathway inhibition assists colon tumor regression via necroptosis.
Necroptosis and Cancer.
Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases.
Necroptosis induced by RIPK3 requires MLKL but not Drp1.
Necroptosis turns TNF lethal.
Necroptosis: a crucial pathogenic mediator of human disease.
NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis.
Neutrophil-rich anaplastic large cell lymphoma of the skull presenting after head trauma.
Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases.
Novel permissive role of epidermal growth factor in transforming growth factor beta (TGF-beta) signaling and growth suppression. Mediation by stabilization of TGF-beta receptor type II.
Novel PPP1CB-ALK fusion in spindle cell tumor defined by S100 and CD34 coexpression and distinctive stromal and perivascular hyalinization.
Novel Transforming Growth Factor-Beta Receptor 1 Antagonists through a Pharmacophore-Based Virtual Screening Approach.
Ophiopogonin D', a Natural Product From Radix Ophiopogonis, Induces in Vitro and in Vivo RIPK1-Dependent and Caspase-Independent Apoptotic Death in Androgen-Independent Human Prostate Cancer Cells.
Overexpression of transforming growth factor beta-type II receptor reduces tumorigenicity and metastastic potential of K-ras-transformed thyroid cells.
p53 brings a new twist to the Smad signaling network.
P7170: a novel molecule with unique profile of mTORC1/C2 and Activin Receptor-Like Kinase 1 inhibition leading to anti-tumor and anti-angiogenic activity.
Paratesticular fibrous pseudotumor: a morphologic and immunohistochemical study of 13 cases.
Parotid Gland Solitary Fibrous Tumor: A Case Report and Clinicopathologic Review of 22 Cases from the Literature.
Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.
Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.
Plasmablastic lymphoma may occur as a high-grade transformation from plasmacytoma.
Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage.
Primary anaplastic large cell lymphoma in the dura of the brain: case report and prediction of a favorable prognosis.
Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression.
Primary CD30/ALK-1 positive anaplastic large cell lymphoma of the skeletal muscle in a child.
Primary Gastric ALK-negative EBV-negative Anaplastic Large Cell Lymphoma Presenting with Iron Deficiency Anemia.
Primary mediastinal anaplastic alk-1-positive large-cell lymphoma of T/NK-cell type expressing CD20.
Pro-necrotic molecules impact local immunosurveillance in human breast cancer.
Processing of CD109 by furin and its role in the regulation of TGF-beta signaling.
Prognostic implications of BAX and TGFBRII mutations in colon cancers with microsatellite instability.
Prognostic role of ALK-1 and h-TERT expression in glioblastoma multiforme: correlation with ALK gene alterations.
Prognostic Significance of CHIP and RIPK3 in Non-Small Cell Lung Cancer.
Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients.
Programmed necrosis - a new mechanism of steroidogenic luteal cell death and elimination during luteolysis in cows.
Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand.
Pseudosarcomatous myofibroblastic proliferations of the bladder: a clinicopathologic study of 42 cases.
Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation.
Quantitative analysis of the secretome of TGF-beta Signaling-deficient mammary fibroblasts.
Receptor-Interacting Protein Kinase 1 Promotes Cholangiocarcinoma Proliferation And Lymphangiogenesis Through The Activation Protein 1 Pathway.
Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension.
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.
Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma.
Reduction of invasive potential in K-ras-transformed thyroid cells by restoring of TGF-beta pathway.
Regulated necrosis-related molecule mRNA expression in humans and mice and in murine acute tissue injury and systemic autoimmunity leading to progressive organ damage, and progressive fibrosis.
Regulation and repurposing of nutrient sensing and autophagy in innate immunity.
Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells.
Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling.
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.
Relationship between intratumor histological heterogeneity and genetic abnormalities in gastric carcinoma with microsatellite instability.
Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells.
Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
RIPK1 binds to vitamin D receptor and decreases vitamin D-induced growth suppression.
RIPK1 both positively and negatively regulates RIPK3 oligomerization and necroptosis.
RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis.
RIPK1 polymorphisms alter the susceptibility to cervical Cancer among the Uyghur population in China.
RIPK1 protects from TNF-?-mediated liver damage during hepatitis.
RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis.
RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer.
RIPK1 suppresses apoptosis mediated by TNF and caspase-3 in intervertebral discs.
RIPK1 ubiquitination: Evidence, correlations and the undefined.
RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function.
RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment.
RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition.
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer.
RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1? release, and efficient paracrine dendritic cell activation.
RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping.
RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells.
RIPK3 Slams the Brake on Leukemogenesis.
RIPK3 Suppresses the Progression of Spontaneous Intestinal Tumorigenesis.
RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence.
RIPK3-a predictive marker for personalized immunotherapy?
RIPK3-Dependent Necroptosis Limits PRV Replication in PK-15 Cells.
Ripk3-induced inflammation by I-MDSCs promotes intestinal tumors.
RIPK3-Mediated Necroptosis Promotes Donor Kidney Inflammatory Injury and Reduces Allograft Survival.
Role of growth factors in pancreatic cancer.
Role of TGF-beta 1 and TGF-beta type II receptor in gastric cancer.
Role of tissue stroma in cancer cell invasion.
Roles for the type III TGF-beta receptor in human cancer.
Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.
Sensing invasion: Cell surface receptors driving spreading of glioblastoma.
Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells.
Shortened ALK1 regulatory fragment maintains a specific activity in arteries feeding ischemic tissues.
Signaling by members of the TGF-beta family in vascular morphogenesis and disease.
Sinonasal IgG4-related disease: a rare and emerging entity broadening the differential diagnosis in the sinonasal universe.
Smac mimetic promotes TNF-? to induce apoptosis of gallbladder carcinoma cells.
Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
Smad7 abrogates transforming growth factor-beta1-mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein.
Soluble transforming growth factor beta type II receptor attenuates TGF-beta1 activity in human colorectal cancer LoVo cells.
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma.
Somatic frameshift mutations of bone morphogenic protein receptor 2 gene in gastric and colorectal cancers with microsatellite instability.
Specificity and Structure of a High Affinity Activin Receptor-like Kinase 1 (ALK1) Signaling Complex.
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Statin Use After Diagnosis of Colon Cancer and Patient Survival.
Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma.
Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).
Synthesis and evaluation of the epithelial-to- mesenchymal inhibitory activity of indazole-derived imidazoles as dual ALK5/p38? MAP inhibitors.
Systemic anaplastic large cell lymphoma presenting as a bladder neoplasm.
TACE-mediated ectodomain shedding of the type I TGF-beta receptor downregulates TGF-beta signaling.
TAK1 regulates endothelial cell necroptosis and tumor metastasis.
Targeting RIP Kinases in Chronic Inflammatory Disease.
Targeting RIPK1 in AML cells carrying FLT3-ITD.
TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.
TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma.
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
TGF-beta signaling in breast cancer.
Tgf-Beta superfamily receptors-targets for antiangiogenic therapy?
TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology.
TGF-{beta} type II Receptor mRNA in Retinoblastoma Cell Lines is induced by Trichostatin A.
TGFBR1 variants TGFBR1(*)6A and Int7G24A are not associated with an increased familial colorectal cancer risk.
TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer.
Tgfbr2 inactivation facilitates cellular plasticity and development of Pten-null prostate cancer.
The Autophagy-Initiating Kinase ULK1 Controls RIPK1-Mediated Cell Death.
The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer.
The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers.
The double life of RIPK1.
The Expression of Activin Receptor-Like Kinase 1 among Patients with Head and Neck Cancer.
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.
The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study.
The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature.
The RING finger protein11 binds to Smad4 and enhances Smad4-dependant TGF-beta signalling.
The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma.
The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression.
The TGFBR1*6A allele is not associated with susceptibility to colorectal cancer in a Spanish population: a case-control study.
The Trend of ripk1/ripk3 and mlkl Mediated Necroptosis Pathway in Patients with Different Stages of Prostate Cancer as Promising Progression Biomarkers.
The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.
The type III TGF-{beta} receptor regulates epithelial and cancer cell migration through {beta}-arrestin2-mediated activation of Cdc42.
The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
The upregulation of expressed proteins in HepG2 cells transfected by the recombinant plasmid-containing HBx gene.
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
TNF-induced necroptosis initiates early autophagy events via RIPK3-dependent AMPK activation, but inhibits late autophagy.
TNF-mediated alveolar macrophage necroptosis drives disease pathogenesis during respiratory syncytial virus infection.
TNF? drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling.
TRADD Mediates RIPK1-Independent Necroptosis Induced by Tumor Necrosis Factor.
TRAF2 is a biologically important necroptosis suppressor.
Transforming growth factor beta and prostate cancer.
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Transforming growth factor beta receptors in verrucous and squamous cell carcinoma.
Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis.
Transforming growth factor beta stimulation of colorectal cancer cell lines: type II receptor bypass and changes in adhesion molecule expression.
Transforming growth factor beta type I receptor acts as a potent tumor suppressor in rat bladder carcinoma.
Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer.
Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia.
Transforming growth factor-beta expression in human testicular neoplasms.
Transforming growth factor-beta expression in prostate neoplasia.
Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth.
Transforming growth factor-beta pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes.
Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor.
Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.
Transforming growth factor-beta receptors in human cancer cell lines: analysis of transcript, protein and proliferation.
Transforming growth factor-beta signaling in cancer.
Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways.
Transforming growth factor-beta type II receptor confers tumor suppressor activity in murine renal carcinoma (Renca) cells.
Transforming growth factor-beta1 and prostate cancer.
Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation.
Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene.
Tubular epithelial cells in renal clear cell carcinoma express high RIPK1/3 and show increased susceptibility to TNF receptor 1-induced necroptosis.
Tumor suppressor activity of the TGF-beta pathway in human cancers.
Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer.
Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.
Tumour progression in experimental oral carcinogenesis is associated with changes in EGF and TGF-beta receptor expression and altered responses to these growth factors.
Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis.
Uncommon TGFBRI allele is not associated with increased susceptibility to colon cancer.
Unique and selective effects of five Ets family members, Elf3, Ets1, Ets2, PEA3, and PU.1, on the promoter of the type II transforming growth factor-beta receptor gene.
Upregulation of transforming growth factor-beta type I receptor by interferon consensus sequence-binding protein in osteosarcoma cells.
Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder.
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
Widespread mitochondrial depletion via mitophagy does not compromise necroptosis.
ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer.
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
[Expression and clinical significance of receptor-interacting protein serine-threonine kinases 1 in the nucleus pulposus of patients with lumbar disc herniation].
[Functional significance of TGF-beta1 signal transduction pathway in oral squamous cell carcinoma]
[Identification of the isoform in type II receptor of transforming growth factor-beta in patients with acute leukemia and its clinical significance]
[Loeys-Dietz syndrome with acute myeloid leukemia]
[Mechanism of resistance to growth inhibition by transforming growth factor-beta 1 (TGF-beta 1) in primary lung cancer and new molecular targets in therapy]
[Small-cell variant of CD30+ -anaplastic large-cell lymphoma of the skin]
Nephritis
Dietary salt intake modulates progression of antithymocyte serum nephritis through alteration of glomerular angiotensin II receptor expression.
Dynamic expression patterns of transforming growth factor-beta(2) and transforming growth factor-beta receptors in experimental glomerulonephritis.
Immune-Mediated Nephropathy and Systemic Autoimmunity in Mice Does Not Require Receptor Interacting Protein Kinase 3 (RIPK3).
Immunoelectron microscopic study on type I, II and III TGF-beta receptors on visceral glomerular epithelial cells in relation to glomerular basement membrane alterations in proteinuric rats.
Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
RIPK3-deficient mice were not protected from nephrotoxic nephritis.
Transforming growth factor-beta receptors in self-limited vs. chronic progressive nephritis in rats.
Nephrosis
Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy.
Nephrosis, Lipoid
Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis.
Nesidioblastosis
Hyperinsulinemic hypoglycemia with nesidioblastosis: histologic features and growth factor expression.
Neuroblastoma
24(S)-Hydroxycholesterol induces RIPK1-dependent but MLKL-independent cell death in the absence of caspase-8.
Disrupted transforming growth factor-beta signaling in spinal and bulbar muscular atrophy.
Participation of type II protein kinase A in the retinoic acid-induced growth inhibition of SH-SY5Y human neuroblastoma cells.
Phosphorylation of endogenous proteins by adenosine 3':5'-monophosphate-dependent protein kinase in mouse neuroblastoma cells.
Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas.
Neurodegenerative Diseases
Necroptosis: a crucial pathogenic mediator of human disease.
Targeting RIPK1 for the treatment of human diseases.
Neuroinflammatory Diseases
Expression of Ripk1 and DAM genes correlates with severity and progression of Krabbe disease.
Inhibiting RIPK1 Limits Neuroinflammation and Alleviates Postoperative Cognitive Impairments in D-Galactose-Induced Aged Mice.
Inhibition of microglial receptor-interacting protein kinase 1 ameliorates neuroinflammation following cerebral ischaemic stroke.
Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases.
Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-?-cyclodextrin.
NEK1-mediated retromer trafficking promotes blood-brain barrier integrity by regulating glucose metabolism and RIPK1 activation.
Outcomes of RIP Kinase Signaling During Neuroinvasive Viral Infection.
RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosis.
RIPK3 Promotes JEV Replication in Neurons via Downregulation of IFI44L.
RIPK3 Restricts Viral Pathogenesis via Cell Death-Independent Neuroinflammation.
RIPped for neuroinflammation.
TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging.
Tuning Apoptosis and Neuroinflammation: TBK1 Restrains RIPK1.
Neuroma, Acoustic
Expression of transforming growth factor-beta receptor type 1 and type 2 in human sporadic vestibular Schwannoma.
Nevus
Absence of RIPK3 predicts necroptosis resistance in malignant melanoma.
Newcastle Disease
Viral strategies for triggering and manipulating mitophagy.
Non-alcoholic Fatty Liver Disease
ATP Citrate Lyase and LncRNA NONMMUT010685 Play Crucial Role in Nonalcoholic Fatty Liver Disease Based on Analysis of Microarray Data.
Influence of Fat on Differential Receptor Interacting Serine/Threonine Protein Kinase 1 Activity Leading to Apoptotic Cell Death in Murine Liver Ischemia Reperfusion Injury Through Caspase 8.
Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
RIPK1 targeting protects against obesity and atherosclerosis.
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
non-specific protein-tyrosine kinase deficiency
c-Abl promotes osteoblast expansion by differentially regulating canonical and non-canonical BMP pathways and p16INK4a expression.
Non-ST Elevated Myocardial Infarction
Changes in plasma levels of RIPK1, RIPK3, and MLKL in patients with coronary atherosclerotic heart disease and its clinical predictive value.
Obesity
Activin Receptor-like Kinase 7 Suppresses Lipolysis to Accumulate Fat in Obesity Through Downregulation of Peroxisome Proliferator-Activated Receptor ? and C/EBP?
Alteration of TGFB1, GDF9, and BMPR2 gene expression in preantral follicles of an estradiol valerate-induced polycystic ovary mouse model can lead to anovulation, polycystic morphology, obesity, and absence of hyperandrogenism.
Diving deep-multipronged investigations into RIPK1 as a risk factor for obesity.
Genetic and evolutionary analyses of the human bone morphogenetic protein receptor 2 (BMPR2) in the pathophysiology of obesity.
Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression.
Publisher Correction: RIPK1 gene variants associate with obesity in humans and can be therapeutically silenced to reduce obesity in mice.
RIPK1 gene variants associate with obesity in humans and can be therapeutically silenced to reduce obesity in mice.
RIPK1 targeting protects against obesity and atherosclerosis.
Obstetric Labor, Premature
Differential expression of transforming growth factor-beta 1 and transforming growth factor-beta receptors in myometrium of women with failed induction of labor, no labor, and preterm labor.
Odontogenic Tumors
Immunoexpression of BMP-2 and BMP-4 and their receptors, BMPR-IA and BMPR-II, in ameloblastomas and adenomatoid odontogenic tumors.
Osteoarthritis
Cripto favors chondrocyte hypertrophy via TGF-? SMAD1/5 signaling during development of osteoarthritis.
Decreased RIPK1 expression in chondrocytes alleviates osteoarthritis via the TRIF/MyD88-RIPK1-TRAF2 negative feedback loop.
Osteoarthritis year 2010 in review: pathomechanisms.
Osteolysis
The effect of adenovirus-mediated siRNA targeting BMPR-II on UHMWPE-induced osteoclast formation.
Osteonecrosis
Exosomal miR-100-5p inhibits osteogenesis of hBMSCs and angiogenesis of HUVECs by suppressing the BMPR2/Smad1/5/9 signalling pathway.
PPARgamma-2 and BMPR2 genes were differentially expressed in peripheral blood of SLE patients with osteonecrosis.
PPARgamma-2 and BMPR2 Genes Were Significantly Differentially Expressed in Peripheral Blood of SLE Patients with Osteonecrosis.
Osteoporosis
Characterisation of genetic regulatory effects for osteoporosis risk variants in human osteoclasts.
Osteosarcoma
BMPR1A is necessary for chondrogenesis and osteogenesis, whereas BMPR1B prevents hypertrophic differentiation.
BMPR2 and HIF1-
BMPR2 expression level is correlated with low immune infiltration and predicts metastasis and poor survival in osteosarcoma.
BMPR2 promotes invasion and metastasis via the RhoA-ROCK-LIMK2 pathway in human osteosarcoma cells.
Expression of bone morphogenetic proteins and receptors in sarcomas.
IAP antagonists sensitize murine osteosarcoma cells to killing by TNF?.
Inhibition of BMP receptor synthesis by antisense oligonucleotides attenuates OP-1 action in primary cultures of fetal rat calvaria cells.
Int7G24A variant of transforming growth factor-beta receptor 1 is associated with osteosarcoma susceptibility in a Chinese population.
Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells.
Upregulation of transforming growth factor-beta type I receptor by interferon consensus sequence-binding protein in osteosarcoma cells.
Otosclerosis
Signaling by way of type IB and II bone morphogenetic protein receptors regulates bone formation in otospongiosis.
Ovarian Neoplasms
A transforming growth factor-beta receptor-interacting protein frequently mutated in human ovarian cancer.
Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7.
Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells.
Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients.
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.
Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling.
MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance.
Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells.
Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors.
TCEA3 binds to TGF-beta receptor I and induces Smad-independent, JNK-dependent apoptosis in ovarian cancer cells.
Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma.
Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-? signaling.
Pancreatic Neoplasms
Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo.
Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer.
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
Interaction of Polymorphisms in Mitotic Regulator Genes With Cigarette Smoking and Pancreatic Cancer Risk.
Ligand induced upregulation of the type II transforming growth factor (TGF-beta) receptor enhances TGF-beta responsiveness in COLO-357 cells.
Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer.
Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage.
Role of growth factors in pancreatic cancer.
Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis.
Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer.
Trichostatin A induces transforming growth factor beta type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex.
Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta1 in COLO-357 cells.
Pancreatitis
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
Suppression of transforming growth factor beta signalling aborts caerulein induced pancreatitis and eliminates restricted stimulation at high caerulein concentrations.
Pancreatitis, Chronic
Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis.
Fibrogenesis in alcoholic chronic pancreatitis: the role of tissue necrosis, macrophages, myofibroblasts and cytokines.
Paralysis
Paediatric pulmonary hypertension caused by an ACVRL1 mutation presenting as Ortner syndrome.
Paramyxoviridae Infections
Emerging views of mitophagy in immunity and autoimmune diseases.
Viral strategies for triggering and manipulating mitophagy.
Parkinson Disease
Regulation of a distinct activated RIPK1 intermediate bridging complex I and complex II in TNF?-mediated apoptosis.
RIPK1 inhibitor ameliorates the MPP+/MPTP-induced Parkinson's disease through the ASK1/JNK signalling pathway.
Parkinsonian Disorders
Emerging views of mitophagy in immunity and autoimmune diseases.
Penile Induration
IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease.
Vactosertib, a Novel, Orally Bioavailable Activin Receptor-Like Kinase 5 Inhibitor, Promotes Regression of Fibrotic Plaques in a Rat Model of Peyronie's Disease.
Perinatal Death
RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis.
Periodontitis
Loss of periodontal ligament fibroblasts by RIPK3-MLKL-mediated necroptosis in the progress of chronic periodontitis.
Peritonitis
Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis.
Pheochromocytoma
Nerve growth factor mediates activation of the Smad pathway in PC12 cells.
Pituitary Neoplasms
Abnormalities in expression of genes, mRNA, and proteins of transforming growth factor-beta receptor type I and type II in human pituitary adenomas.
Plasmacytoma
Resolution and general properties of different types of ribosomal protein kinases in mouse plasmocytoma.
Pneumonia
Interventions and mechanisms of N-acetylcysteine on monocrotaline-induced pulmonary arterial hypertension.
Involvement of Alveolar Epithelial Cell Necroptosis in IPF Pathogenesis.
Phenotypically-Silent Bone Morphogenetic Protein Receptor 2 (Bmpr2) Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing The Risk for Neointimal Transformation.
RIPK3 Activates MLKL-mediated Necroptosis and Inflammasome Signaling during Streptococcus Infection.
TBK1/IKK? Negatively Regulate LPS-Induced Neutrophil Necroptosis and Lung Inflammation.
TREM-1 Attenuates RIPK3 Mediated Necroptosis in Hyperoxia Induced Lung Injury in Neonatal Mice.
Pneumonia, Pneumococcal
RIPK3 Activates MLKL-mediated Necroptosis and Inflammasome Signaling during Streptococcus Infection.
Pneumothorax
Expression of TGF-beta receptor 1 and Smads in the tissues of primary spontaneous pneumothorax.
Pneumovirus Infections
RSV Infection Promotes Necroptosis and HMGB1 Release by Airway Epithelial Cells.
Polycystic Ovary Syndrome
Single-cell expression analysis of BMP15 and GDF9 in mature oocytes and BMPR2 in cumulus cells of women with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation.
Porcine Reproductive and Respiratory Syndrome
Molecular Markers of MDR of Chemotherapy for HSCC: Proteomic Screening With High-Throughput Liquid Chromatography-Tandem Mass Spectrometry.
Viral strategies for triggering and manipulating mitophagy.
Poroma
Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma.
Pre-Eclampsia
Gene expression profiling of placentae from women with early- and late-onset pre-eclampsia: down-regulation of the angiogenesis-related genes ACVRL1 and EGFL7 in early-onset disease.
Key players of the necroptosis pathway RIPK1 and SIRT2 are altered in placenta from preeclampsia and fetal growth restriction.
Nodal signals through activin receptor-like kinase 7 to inhibit trophoblast migration and invasion: implication in the pathogenesis of preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Expression and significance of TGF-beta1, TbetaRII and c-myc in patients with acute leukemia]
Primary Ovarian Insufficiency
A potential functional association between mutant BMPR2 and primary ovarian insufficiency.
Prolactinoma
Mutational analysis of transforming growth factor-beta receptor type II and Smad3 tumor suppressor genes in prolactinomas.
Prostatic Hyperplasia
Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-beta receptor expression.
Transforming growth factor-beta expression in prostate neoplasia.
Prostatic Intraepithelial Neoplasia
Transforming growth factor-beta expression in prostate neoplasia.
Prostatic Neoplasms
Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells.
Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
BMPRII is a direct target of miR-21.
Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone.
Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4.
Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening.
CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells.
Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues.
Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells.
Growth regulation of human prostate cancer cells by bone morphogenetic protein-2.
Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
Insensitivity to transforming growth factor-beta results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP).
Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers.
miR-20b-5p, TGFBR2, and E2F1 Form a Regulatory Loop to Participate in Epithelial to Mesenchymal Transition in Prostate Cancer.
More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.
Prohibitin and Cofilin Are Intracellular Effectors of Transforming Growth Factor {beta} Signaling in Human Prostate Cancer Cells.
Promoter methylation reduces expression of TGF-beta receptor type 2 gene in prostate cancer.
Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study.
Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Role of bone morphogenetic proteins in human prostate cancer pathogenesis and development of bone metastases: immunohistochemical study.
Role of transforming growth factor-beta1 in prostate cancer.
The Trend of ripk1/ripk3 and mlkl Mediated Necroptosis Pathway in Patients with Different Stages of Prostate Cancer as Promising Progression Biomarkers.
The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
Transforming growth factor beta and prostate cancer.
Transforming growth factor-beta1 and prostate cancer.
Transforming growth factor-{beta} receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate?
protein acetyllysine n-acetyltransferase deficiency
SIRT3 deficiency delays diabetic skin wound healing via oxidative stress and necroptosis enhancement.
Sirtuin 3 deficiency exacerbates diabetic cardiomyopathy via necroptosis enhancement and NLRP3 activation.
Psoriasis
Down-regulation of transforming growth factor-beta receptors I and II is seen in lesional but not non-lesional psoriatic epidermis.
Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation.
Receptor-interacting Protein Kinase 3 Controls Keratinocyte Activation in a Necroptosis-independent Manner and Promotes Psoriatic Dermatitis in Mice.
Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled Study.
RIPK1 downregulation in keratinocyte enhances TRAIL signaling in psoriasis.
Pulmonary Arterial Hypertension
4PBA Restores Signaling of a Cysteine-substituted Mutant BMPR2 Receptor Found in Patients with Pulmonary Arterial Hypertension.
5-HTT, BMPR2, EDN1, ENG, KCNA5 gene polymorphisms and susceptibility to pulmonary arterial hypertension: A meta-analysis.
A burden of rare variants in BMPR2 and KCNK3 contributes to a risk of familial pulmonary arterial hypertension.
A dual-light reporter system to determine the efficiency of protein-protein interactions in mammalian cells.
A novel BMPR2 mutation associated with pulmonary arterial hypertension in an octogenarian.
A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype.
A novel break point of the BMPR2 gene exonic deletion in a patient with pulmonary arterial hypertension.
A novel mutation in the BMPR2 gene in familial pulmonary arterial hypertension.
A novel piperidine identified by stem cell-based screening attenuates pulmonary arterial hypertension by regulating BMP2 and PTGS2 levels.
Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension.
Activin receptor-like kinase 1 is essential for placental vascular development in mice.
ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension.
Alu-mediated nonallelic homologous and nonhomologous recombination in the BMPR2 gene in heritable pulmonary arterial hypertension.
AN HOMOZYGOUS MUTATION IN KCNK3 IS ASSOCIATED WITH AN AGGRESSIVE FORM OF HEREDITARY PULMONARY ARTERIAL HYPERTENSION.
Approaches to treat pulmonary arterial hypertension by targeting bmpr2 - from cell membrane to nucleus.
BMP and activin type-II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.
BMP Pathway Regulation of and by Macrophages.
BMP9 and BMP10: two close vascular quiescence partners that stand out.
BMPR-II mutations promote pulmonary arterial hypertension via a hyperinflammatory response.
BMPR2 expression is suppressed by signaling through the estrogen receptor.
BMPR2 gene mutation in pulmonary arteriovenous malformation and pulmonary hypertension: a case report.
BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension.
BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension.
Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
BMPR2 mutation and outcome in pulmonary arterial hypertension: clinical relevance to physicians and patients.
BMPR2 Mutation Carriers: Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension Without Symptoms: Cautionary Tales?
BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia.
BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension.
BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.
BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.
BMPR2 Mutations Influence Phenotype More Obviously in Male Patients with Pulmonary Arterial Hypertension.
BMPR2 Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients.
BMPRII deficiency impairs apoptosis via the BMPRII-ALK1-BclX-mediated pathway in pulmonary arterial hypertension.
Bone morphogenetic protein receptor II is a novel mediator of eNOS activation.
Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.
Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors.
Bone morphogenetic protein signaling is required for RAD51-mediated maintenance of genome integrity in vascular endothelial cells.
Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of BMPRII.
Characterization of the BMPR2 5'-untranslated region and a novel mutation in pulmonary hypertension.
Clinical characteristics and survival of Chinese patients diagnosed with pulmonary arterial hypertension who carry BMPR2 or EIF2KAK4 variants.
Clinical Features of Pulmonary Arterial Hypertension in Young People with an ALK1 Mutation and Hereditary Hemorrhagic Telangiectasia.
Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension.
Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.
Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.
Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2.
Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension.
Connectivity Map Analysis of NMD+ BMPR2 Related HPAH Provides Insights into Disease Penetrance.
Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension.
Contribution of oxidative stress to endothelial dysfunction in hereditary hemorrhagic telangiectasia.
Contributions of BMPR2 Mutations and Extrinsic Factors to Cellular Phenotypes of Pulmonary Arterial Hypertension Revealed by iPSC Modeling.
Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors.
Copy-number variation in BMPR2 is not associated with the pathogenesis of pulmonary arterial hypertension.
Correction of Nonsense BMPR2 and SMAD9 Mutations by Ataluren in Pulmonary Arterial Hypertension.
Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension.
Cytokines trigger disruption of endothelium barrier function and p38 MAP kinase activation in BMPR2-silenced human lung microvascular endothelial cells.
Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension.
Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2.
Deletion of the sequence encoding the tail domain of the bone morphogenetic protein type 2 receptor reveals a bone morphogenetic protein 7-specific gain of function.
Different forms of pulmonary hypertension in a family with clinical and genetic evidence for hereditary hemorrhagic teleangectasia type 2.
Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension.
Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension.
Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension.
Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension.
Early onset severe pulmonary arterial hypertension with 'two-hit' digenic mutations in both BMPR2 and KCNA5 genes.
Emerging role of bone morphogenetic proteins in angiogenesis.
Endoplasmic Reticulum Associated Protein Degradation (ERAD) in the Pathology of Diseases Related to TGF? Signaling Pathway: Future Therapeutic Perspectives.
Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling.
Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma.
Estrogen Receptor Alpha in Pulmonary Hypertension.
EXPRESS: BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension.
Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue.
Function of Adipose-Derived Mesenchymal Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension through miR-191 via Regulation of BMPR2.
Functional mutations in 5'UTR of the BMPR2 gene identified in Chinese families with pulmonary arterial hypertension.
Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: a meta-analysis.
Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary Arterial Hypertension suggests pathways relevant to disease penetrance.
Generation of pulmonary arterial hypertension patient-specific induced pluripotent stem cell lines from three unrelated patients with a heterozygous missense mutation in exon 12, a heterozygous in-frame deletion in exon 3 and a missense mutation in exon 11 of the BMPR2 gene.
Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension.
Genetic counselling in a national referral centre for pulmonary hypertension.
Genetic variants in the Polish population of patients with pulmonary arterial hypertension - sequencing of BMPR2, ALK1 and ENG genes.
Genetics of pulmonary hypertension: from bench to bedside.
Heart failure and pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia type 2.
Heart failure and pulmonary hypertension.
Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.
Heritable pulmonary hypertension: from bench to bedside.
High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension.
Hypoxia regulates bone morphogenetic protein signaling through C-terminal-binding protein 1.
Hypoxia-Induced Pulmonary Hypertension in Different Mouse Strains - Relation to Transcriptome.
Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II.
Identification of multiple ACVRL1 mutations in patients with pulmonary arterial hypertension by targeted exome capture.
Idiopathic and heritable PAH perturb common molecular pathways, correlated with increased MSX1 expression.
Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension.
Improved Survival of Patients with Pulmonary Arterial Hypertension with BMPR2 Mutations in the Last Decade.
Improvement of pulmonary arterial hypertension following medication and shunt closure in a BMPR2 mutation carrier with atrial septal defect.
In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and its Target Slug.
Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature.
Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.
Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension.
Lack of circulating autoantibodies to bone morphogenetic protein receptor-II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension.
Loss-of BMPR2 is Associated With Abnormal DNA Repair in Pulmonary Arterial Hypertension.
LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPAR? Activation.
Mate-pair sequencing identifies a cryptic BMPR2 mutation in hereditary pulmonary arterial hypertension.
Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle.
Methylation Analysis of the BMPR2 Gene Promoter Region in Patients With Pulmonary Arterial Hypertension.
Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions.
Modulation of Endothelial BMPR2 Activity by VEGFR3 in Pulmonary Arterial Hypertension.
Molecular Analysis of BMPR2, TBX4, and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families With Idiopathic and Hereditary Pulmonary Arterial Hypertension.
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension.
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension.
Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor.
Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension.
Mutations of NOTCH3 in childhood pulmonary arterial hypertension.
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.
New pathogenic variant of BMPR2 in pulmonary arterial hypertension.
Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity.
Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report.
Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension.
Novel promoter and exon mutations of the BMPR2 gene in Chinese patients with pulmonary arterial hypertension.
Outcomes of Childhood Pulmonary Arterial Hypertension in BMPR2 and ALK1 Mutation Carriers.
Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.
Oxidative stress increases M1dG, a major peroxidation-derived DNA adduct, in mitochondrial DNA.
Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers.
Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele.
PERK inhibition attenuates vascular remodeling in pulmonary arterial hypertension caused by BMPR2 mutation.
Phenotypically-Silent Bone Morphogenetic Protein Receptor 2 (Bmpr2) Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing The Risk for Neointimal Transformation.
PPAR?-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension.
Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation.
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Proteomics of transformed lymphocytes from a family with familial pulmonary arterial hypertension.
Pulmonary arterial hypertension associated with hereditary spherocytosis and splenectomy in a patient with a mutation in the BMPR2 gene.
Pulmonary arterial hypertension preceding idiopathic pulmonary fibrosis in a BMPR2 mutation positive patient.
Pulmonary capillary hemangiomatosis: a focus on the EIF2AK4 mutation in onset and pathogenesis.
Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?
Pulmonary hypertension in hereditary haemorrhagic telangiectasia.
Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations.
Pulmonary Vascular Platform Models the Effects of Flow and Pressure on Endothelial Dysfunction in BMPR2 Associated Pulmonary Arterial Hypertension.
Redox and Inflammatory Signaling, the Unfolded Protein Response, and the Pathogenesis of Pulmonary Hypertension.
Regulation of bone morphogenetic protein signalling in human pulmonary vascular development.
Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension.
Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension.
Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension.
Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations.
Right ventricular and pulmonary vascular reserve in asymptomatic BMPR2 mutation carriers.
RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension.
Role of SMURF1 ubiquitin ligase in BMP receptor trafficking and signaling.
Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation.
SCUBE1 Controls BMPR2-Relevant Pulmonary Endothelial Function: Implications for Diagnostic Marker Development in Pulmonary Arterial Hypertension.
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension.
Significance of BMPR2 mutations in pulmonary arterial hypertension.
Somatic mosaicism in ACVRL1 with transmission to several offspring affected with severe pulmonary arterial hypertension.
Stoichiometric imbalance in the receptor complex contributes to dysfunctional BMPR-II mediated signalling in pulmonary arterial hypertension.
Structural basis for ALK2/BMPR2 receptor complex signaling through kinase domain oligomerization.
Structural consequences of BMPR2 kinase domain mutations causing pulmonary arterial hypertension.
SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling.
Subcellular mechanisms in pulmonary arterial hypertension: combinatorial modalities that inhibit anterograde trafficking and cause bone morphogenetic protein receptor type 2 mislocalization.
Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension.
Targeting BMPR2 Trafficking with Chaperones: An Important Step toward Precision Medicine in Pulmonary Arterial Hypertension.
Targeting translational read-through of premature termination mutations in BMPR2 with PTC124 for pulmonary arterial hypertension.
TGF-beta and BMPR-II pharmacology-implications for pulmonary vascular diseases.
TGF? and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension.
The BMPR2 missense mutation p.K230N and pulmonary arterial hypertension.
The Effects of Mercaptopurine on Pulmonary Vascular Resistance and BMPR2 Expression in Pulmonary Arterial Hypertension.
The Efficacy of a Genetic Analysis of the BMPR2 Gene in a Patient with Severe Pulmonary Arterial Hypertension and an Atrial Septal Defect Treated with Bilateral Lung Transplantation.
The features of rare pathogenic BMPR2 variants in pulmonary arterial hypertension: Comparison between patients and reference population.
The flavonoid quercetin reverses pulmonary hypertension in rats.
The P2-receptor-mediated Ca2+ signalosome of the human pulmonary endothelium - implications for pulmonary arterial hypertension.
The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension.
Three novel BMPR2 mutations associated with advanced pulmonary arterial hypertension.
Towards Systems Biology of Pulmonary Hypertension.
Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood.
What patients and their relatives think about testing for BMPR2.
[Analysis of genetic mutation and modifier genes in pulmonary arterial hypertension]
[Bone morphogenetic protein type II receptor gene promoter mutation-142G > A in a patient with familial pulmonary arterial hypertension]
[Study of the BMPR2 gene in patients with pulmonary arterial hypertension]
Pulmonary Disease, Chronic Obstructive
A Functional Variant rs6435156C > T in BMPR2 is Associated With Increased Risk of Chronic Obstructive Pulmonary Disease (COPD) in Southern Chinese Population.
Necroptosis Signaling Promotes Inflammation, Airway Remodeling, and Emphysema in Chronic Obstructive Pulmonary Disease.
Smads as intracellular mediators of airway inflammation.
Pulmonary Embolism
Accuracy of Echocardiography to Evaluate Pulmonary Vascular and RV Function During Exercise.
High Frequency of Pulmonary Hypertension-Causing Gene Mutation in Chinese Patients with Chronic Thromboembolic Pulmonary Hypertension.
Pulmonary Fibrosis
A homozygous SFTPA1 mutation drives necroptosis of type II alveolar epithelial cells in patients with idiopathic pulmonary fibrosis.
Expression of mutant bone morphogenetic protein receptor II worsens pulmonary hypertension secondary to pulmonary fibrosis.
Expression of transforming growth factor-beta type I and type II receptors is altered in rat lungs undergoing bleomycin-induced pulmonary fibrosis.
Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.
Necrostatin-1 Alleviates Bleomycin-Induced Pulmonary Fibrosis and Extracellular Matrix Expression in Interstitial Pulmonary Fibrosis.
Progressive Transforming Growth Factor {beta}1-induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor.
Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis.
Pulmonary Veno-Occlusive Disease
BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension.
Genetic counselling in a national referral centre for pulmonary hypertension.
receptor protein serine/threonine kinase deficiency
ABIN-1 regulates RIPK1 activation by linking Met1 ubiquitylation with Lys63 deubiquitylation in TNF-RSC.
Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation.
BMP type II receptor deficiency confers resistance to growth inhibition by TGF-? in pulmonary artery smooth muscle cells: role of proinflammatory cytokines.
BMP-9 and LDL crosstalk regulates ALK-1 endocytosis and LDL transcytosis in endothelial cells.
BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of TGF?-TAK1-MAPK pathways in PAH.
BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGF? responses and altered cell mechanics.
BMPR2 promotes fatty acid oxidation and protects white adipocytes from cell death in mice.
BMPRII deficiency impairs apoptosis via the BMPRII-ALK1-BclX-mediated pathway in pulmonary arterial hypertension.
Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.
Caspase-8 mediates caspase-1 processing and innate immune defense in response to bacterial blockade of NF-?B and MAPK signaling.
Caspase-8 restricts natural killer cell accumulation during MCMV Infection.
Clinical phenotype of a Chinese patient with RIPK1 deficiency due to novel mutation.
Combination of IAP antagonist and IFN? activates novel caspase-10- and RIPK1-dependent cell death pathways.
Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension.
Cutting edge: RIPK1 Kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo.
Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling.
Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH.
Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis.
Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases.
Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable.
Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis.
Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia.
MLKL contributes to Western diet-induced liver injury through inhibiting autophagy.
Myeloid tumor necrosis factor and heme oxygenase-1 regulate the progression of colorectal liver metastases during hepatic ischemia-reperfusion.
Necroptosis and Inflammation.
Necroptosis Signaling Promotes Inflammation, Airway Remodeling, and Emphysema in Chronic Obstructive Pulmonary Disease.
Phenotypically-Silent Bone Morphogenetic Protein Receptor 2 (Bmpr2) Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing The Risk for Neointimal Transformation.
Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells.
Receptor-interacting protein kinase 3 deficiency inhibits immune cell infiltration and attenuates organ injury in sepsis.
RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome.
RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury.
RIPK1 and RIPK3: critical regulators of inflammation and cell death.
RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis.
RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis.
RIPK3 Activates MLKL-mediated Necroptosis and Inflammasome Signaling during Streptococcus Infection.
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
RIPK3 and Caspase-1/11 Are Necessary for Optimal Antigen-Specific CD8 T Cell Response Elicited by Genetically Modified Listeria monocytogenes.
RIPK3 as a potential therapeutic target for Gaucher's disease.
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
Ripk3 induces mitochondrial apoptosis via inhibition of FUNDC1 mitophagy in cardiac IR injury.
RIPK3 mediates pathogenesis of experimental ventilator-induced lung injury.
RIPK3 orchestrates fatty acid metabolism in tumor-associated macrophages and hepatocarcinogenesis.
Ripk3 regulates cardiac microvascular reperfusion injury: The role of IP3R-dependent calcium overload, XO-mediated oxidative stress and F-action/filopodia-based cellular migration.
RIPK3-Mediated Necroptosis in Diabetic Cardiomyopathy Requires CaMKII Activation.
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
Sequential activation of necroptosis and apoptosis cooperates to mediate vascular and neural pathology in stroke.
Sharpin prevents skin inflammation by inhibiting TNFR1-induced keratinocyte apoptosis.
Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension.
Survival function of the FADD-CASPASE-8-cFLIP(L) complex.
TAK1 restricts spontaneous NLRP3 activation and cell death to control myeloid proliferation.
The ALK-1/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?
TWEAK and RIPK1 mediate a second wave of cell death during AKI.
Ubiquitination of RIPK1 regulates its activation mediated by TNFR1 and TLRs signaling in distinct manners.
Z-nucleic-acid sensing triggers ZBP1-dependent necroptosis and inflammation.
ZBP1/DAI Drives RIPK3-Mediated Cell Death Induced by IFNs in the Absence of RIPK1.
Rectal Neoplasms
Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer.
Renal Insufficiency
Primidone blocks RIPK1-driven cell death and inflammation.
Renal Insufficiency, Chronic
ALK5 inhibition in renal disease.
BMP type I receptor inhibition attenuates endothelial dysfunction in mice with chronic kidney disease.
Reperfusion Injury
Analyzing Necroptosis Using an RIPK1 Kinase Inactive Mouse Model of TNF Shock.
Combined Knockout of RIPK3 and MLKL Reveals Unexpected Outcome in Tissue Injury and Inflammation.
Expression and genetic polymorphism of necroptosis related protein RIPK1 is correlated with severe hepatic ischemia-reperfusion injury and prognosis after hepatectomy in hepatocellular carcinoma patients.
Influence of Fat on Differential Receptor Interacting Serine/Threonine Protein Kinase 1 Activity Leading to Apoptotic Cell Death in Murine Liver Ischemia Reperfusion Injury Through Caspase 8.
Loss of RIPK3 and Caspase-8 Augments Intrinsic Apoptosis in Tubular Epithelial Cell and promote Kidney Ischemia Reperfusion Injury.
Necroptotic-Apoptotic Regulation in an Endothelin-1 Model of Cerebral Ischemia.
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
Ripk3 induces mitochondrial apoptosis via inhibition of FUNDC1 mitophagy in cardiac IR injury.
Ripk3 regulates cardiac microvascular reperfusion injury: The role of IP3R-dependent calcium overload, XO-mediated oxidative stress and F-action/filopodia-based cellular migration.
RIPK3-deficient mice were not protected from nephrotoxic nephritis.
Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury.
Retinal Degeneration
A novel RIPK1 inhibitor that prevents retinal degeneration in a rat glaucoma model.
Retinal Neovascularization
Remodeling retinal neovascularization by ALK1 gene transfection in vitro.
Retinoblastoma
Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.
TGF-{beta} type II Receptor mRNA in Retinoblastoma Cell Lines is induced by Trichostatin A.
Rhabdomyosarcoma, Embryonal
Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder.
Rhinitis, Allergic
LRG1 downregulation in allergic airway disorders and its expression in peripheral blood and tissue cells.
Rhinitis, Allergic, Seasonal
Nasal mucosal immunoexpression of the mast cell chemoattractants TGF-beta, eotaxin, and stem cell factor and their receptors in allergic rhinitis.
ring-type e3 ubiquitin transferase deficiency
The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome.
Salmonella Infections
Ripk3 licenced protection against microbial infection in the absence of Caspase1-11 inflammasome.
Sandhoff Disease
Expression of Ripk1 and DAM genes correlates with severity and progression of Krabbe disease.
Sarcoma
Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension.
Immunohistochemical analysis of embryonal sarcoma of the liver.
Viral src gene products are related to the catalytic chain of mammalian cAMP-dependent protein kinase.
Sarcoma, Avian
Cytosolic malic dehydrogenase activity is associated with a putative substrate for the transforming gene product of Rous sarcoma virus.
Protein kinase and its regulatory effect on reverse transcriptase activity of Rous sarcoma virus.
Sarcoma, Kaposi
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor.
Schistosomiasis
Hepatic Shunting of Eggs and Pulmonary Vascular Remodeling in Bmpr2(+/-) Mice with Schistosomiasis.
Scimitar Syndrome
Whole-exome sequencing identifies SGCD and ACVRL1 mutations associated with total anomalous pulmonary venous return (TAPVR) in Chinese population.
Scleroderma, Systemic
Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis.
Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts.
Sepsis
Association of plasma level of high-mobility group box-1 with necroptosis and sepsis outcomes.
Association of Plasma Level of TNF-Related Apoptosis-Inducing Ligand with Severity and Outcome of Sepsis.
Distinct cell death markers identified in critical care patient survivors diagnosed with sepsis.
Innate immune priming in the absence of TAK1 drives RIPK1 kinase activity-independent pyroptosis, apoptosis, necroptosis, and inflammatory disease.
N-3-oxododecanoyl homoserine lactone exacerbates endothelial cell death by inducing receptor-interacting protein kinase 1-dependent apoptosis.
Necroptosis Promotes Staphylococcus aureus Clearance by Inhibiting Excessive Inflammatory Signaling.
Necroptosis regulated proteins expression is an early prognostic biomarker in patient with sepsis: a prospective observational study.
P2X1, P2X4, and P2X7 Receptor Knock Out Mice Expose Differential Outcome of Sepsis Induced by ?-Haemolysin Producing Escherichia coli.
Plasma receptor interacting protein kinase-3 levels are associated with acute respiratory distress syndrome in sepsis and trauma: a cohort study.
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target.
Receptor-interacting protein kinase 3 deficiency inhibits immune cell infiltration and attenuates organ injury in sepsis.
RIP kinase 1-dependent endothelial necroptosis underlies systemic inflammatory response syndrome.
RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome.
RIPK3 collaborates with GSDMD to drive tissue injury in lethal polymicrobial sepsis.
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
RIPK3 promotes sepsis-induced acute kidney injury via mitochondrial dysfunction.
Sezary Syndrome
Loss of receptors for transforming growth factor beta in human T-cell malignancies.
Shock, Septic
Necroptosis regulated proteins expression is an early prognostic biomarker in patient with sepsis: a prospective observational study.
Skin Diseases
RIPK1: A rising star in inflammatory and neoplastic skin diseases.
Transforming growth factor-beta receptor expression on human skin fibroblasts: dimeric complex formation of type I and type II receptors and identification of glycosyl phosphatidylinositol-anchored transforming growth factor-beta binding proteins.
When Beauty Is Skin Deep: Regulation of the Wound Response by Caspase-8, RIPK3, and the Inflammasome.
Small Cell Lung Carcinoma
Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines.
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Spinal Cord Injuries
B-RAFV600E Inhibitor Dabrafenib Attenuates RIPK3-Mediated Necroptosis and Promotes Functional Recovery after Spinal Cord Injury.
Changes in Expression of Receptor-Interacting Protein Kinase 1 in Secondary Neural Tissue Damage Following Spinal Cord Injury.
Lysosomal damage after spinal cord injury causes accumulation of RIPK1 and RIPK3 proteins and potentiation of necroptosis.
Squamous Cell Carcinoma of Head and Neck
Aberrant methylation inactivates transforming growth factor Beta receptor I in head and neck squamous cell carcinoma.
Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer.
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Downregulation of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts.
Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis.
Identification of genetic alterations in the TGFbeta type II receptor gene promoter.
Inhibition of TGF-beta1 suppresses motility and invasiveness of oral squamous cell carcinoma cell lines via modulation of integrins and down-regulation of matrix-metalloproteinases.
Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma.
Loss of expression of TGF-beta1, TbetaRI, and TbetaRII correlates with differentiation in human oral squamous cell carcinomas.
Loss of p12CDK2-AP1 expression in human oral squamous cell carcinoma with disrupted transforming growth factor-beta-Smad signaling pathway.
The Expression of Activin Receptor-Like Kinase 1 among Patients with Head and Neck Cancer.
The Expression of Activin Receptor-like Kinase 1 in HNSCC.
ST Elevation Myocardial Infarction
Changes in plasma levels of RIPK1, RIPK3, and MLKL in patients with coronary atherosclerotic heart disease and its clinical predictive value.
Serum levels of RIPK3 and troponin I as potential biomarkers for predicting impaired left ventricular function in patients with myocardial infarction with ST segment elevation and normal troponin I levels prior percutaneous coronary intervention.
Starvation
BOTRYTIS-INDUCED KINASE1, a plasma membrane-localized receptor-like protein kinase, is a negative regulator of phosphate homeostasis in Arabidopsis thaliana.
Smad-mediated transcription is required for transforming growth factor-beta 1-induced p57(Kip2) proteolysis in osteoblastic cells.
Status Epilepticus
Hydrogen Alleviates Necroptosis and Cognitive Deficits in Lithium-Pilocarpine Model of Status Epilepticus.
Stomach Neoplasms
Association between receptor interacting serine/threonine kinase 2 polymorphisms and gastric cancer susceptibility.
Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer.
C23 protein meditates bone morphogenetic protein-2-mediated EMT via up-regulation of Erk1/2 and Akt in gastric cancer.
Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice.
Deregulated bone morphogenetic proteins and their receptors are associated with disease progression of gastric cancer.
Expression of transforming growth factor-beta receptor type II gene in gastric cancer cell lines.
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling.
Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells.
miR-100-3p inhibits cell proliferation and induces apoptosis in human gastric cancer through targeting to BMPR2.
Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck.
Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer.
Stroke
Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels.
Primidone blocks RIPK1-driven cell death and inflammation.
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
Subarachnoid Hemorrhage
Inhibiting of RIPK3 attenuates early brain injury following subarachnoid hemorrhage: Possibly through alleviating necroptosis.
Syncope
Idiopathic pulmonary arterial hypertension associated with a novel frameshift mutation in the bone morphogenetic protein receptor II gene and enhanced bone morphogenetic protein signaling: A case report.
Synostosis
New insights into the molecular mechanism of multiple synostoses syndrome (SYNS): Mutation within the GDF5 knuckle epitope causes noggin-resistance.
Synovitis
The p55TNFR-IKK2-Ripk3 axis orchestrates arthritis by regulating death and inflammatory pathways in synovial fibroblasts.
Telangiectasia, Hereditary Hemorrhagic
12q13.12q13.13 microdeletion encompassing ACVRL1 and SCN8A genes: Clinical report of a new contiguous gene syndrome.
99mTc-MAA Pulmonary Scintigraphy in Hereditary Hemorrhagic Telangiectasia.
A Case of Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia Related to an ACVRL1 Mutation.
A mouse model of hereditary hemorrhagic telangiectasia generated by transmammary-delivered immunoblocking of BMP9 and BMP10.
A novel BMPR2 mutation in a patient with heritable pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia: A case report.
A novel ENG mutation causing impaired co-translational processing of endoglin associated with hereditary hemorrhagic telangiectasia.
A novel mutation in ALK-1 causes hereditary hemorrhagic telangiectasia type 2.
A Novel Variant in the ACVRL1 Gene in a Patient with Cirrhosis and Hereditary Hemorrhagic Telangiectasia
A rare cause of fatal right ventricular cardiac decompensation.
Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs.
Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: potential roles for JNK and ERK.
Activin receptor-like kinase 1 is essential for placental vascular development in mice.
ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension.
ALK-1 mutations in liver transplanted patients with hereditary hemorrhagic telangiectasia.
Alk1 controls arterial endothelial cell migration in lumenized vessels.
ALK1 Signaling Inhibits Angiogenesis by Cooperating with the Notch Pathway.
Allelic dropout in the ENG gene, affecting the results of genetic testing in hereditary hemorrhagic telangiectasia.
An Intron Mutation in the ACVRL1 May Be Associated with a Transcriptional Regulation Defect in a Chinese Family with Hereditary Hemorrhagic Telangiectasia.
Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2.
Arteriovenous malformation in the adult mouse brain resembling the human disease.
Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1.
Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system.
BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II.
BMP9 Mutations Cause a Vascular-Anomaly Syndrome with Phenotypic Overlap with Hereditary Hemorrhagic Telangiectasia.
BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia.
Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors.
Bone morphogenetic protein signaling is required for RAD51-mediated maintenance of genome integrity in vascular endothelial cells.
Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression.
Casein kinase 2{beta} as a novel enhancer of activin-like receptor-1 signaling.
Characterization of pulmonary arteriovenous malformations in ACVRL1 versus ENG mutation carriers in hereditary hemorrhagic telangiectasia.
Clinical and molecular characterization of patients with hereditary hemorrhagic telangiectasia: Experience from an HHT Center of Excellence.
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.
Clinical features and mutations in the ENG, ACVRL1, and SMAD4 genes in Korean patients with hereditary hemorrhagic telangiectasia.
Clinical Features of Pulmonary Arterial Hypertension in Young People with an ALK1 Mutation and Hereditary Hemorrhagic Telangiectasia.
Curaçao diagnostic criteria for hereditary hemorrhagic telangiectasia is highly predictive of a pathogenic variant in ENG or ACVRL1 (HHT1 and HHT2).
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Different forms of pulmonary hypertension in a family with clinical and genetic evidence for hereditary hemorrhagic teleangectasia type 2.
Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels.
Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients.
Effect of Transcriptional Regulator ID3 on Pulmonary Arterial Hypertension and Hereditary Hemorrhagic Telangiectasia.
Endoglin in angiogenesis and vascular diseases.
Endoplasmic Reticulum Associated Protein Degradation (ERAD) in the Pathology of Diseases Related to TGF? Signaling Pathway: Future Therapeutic Perspectives.
ENG mutational mosaicism in a family with hereditary hemorrhagic telangiectasia.
Evidence for the founder effect of a novel ACVRL1 splice-site mutation in Hungarian hereditary hemorrhagic telangiectasia families.
Functional analysis of mutations in the kinase domain of the TGF-beta receptor ALK1 reveals different mechanisms for induction of hereditary hemorrhagic telangiectasia.
Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations.
Functional and splicing defect analysis of 23 ACVRL1 mutations in a cohort of patients affected by Hereditary Hemorrhagic Telangiectasia.
Generation and genetic repair of 2 iPSC clones from a patient bearing a heterozygous c.1120del18 mutation in the ACVRL1 gene leading to Hereditary Hemorrhagic Telangiectasia (HHT) type 2.
Generation of mice with a conditional and reporter allele for Tmem100.
Genetic basis of pulmonary arterial hypertension: current understanding and future directions.
Genetic studies of pulmonary arterial hypertension.
Genetic variants of Adam17 differentially regulate TGF? signaling to modify vascular pathology in mice and humans.
Genotype-Phenotype Correlations in Children with HHT.
Global gene expression profiling of telangiectasial tissue from patients with hereditary hemorrhagic telangiectasia.
Heart failure and pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia type 2.
Hereditary hemorrhagic telangiectasia is caused by the Q490X mutation of the ACVRL1 gene in a large Arab family: support of homozygous lethality.
Hereditary hemorrhagic telangiectasia type 1 and 2 mutations in Finland.
Hereditary Hemorrhagic Telangiectasia: Breakpoint Characterization of a Novel Large Deletion in ACVRL1 Suggests the Causing Mechanism.
Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients.
Hereditary hemorrhagic telangiectasia: evidence for regional founder effects of ACVRL1 mutations in French and Italian patients.
Human retroviral gag- and gag-pol-like proteins interact with the transforming growth factor-beta receptor activin receptor-like kinase 1.
Identification of a Novel ACVRL1 Gene Mutation (c.100T>A, p.Cys34Ser) in a Japanese Patient with Possible Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Disease).
Identifying common genetic variants by high-resolution melting.
Idiopathic pulmonary hypertension: what did we learn from genes?
Impact of genotype and mutation type on health-related quality of life in patients with hereditary hemorrhagic telangiectasia.
Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation.
Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex.
Matrix Gla protein deficiency causes arteriovenous malformations in mice.
Minimal homozygous endothelial deletion of Eng with VEGF stimulation is sufficient to cause cerebrovascular dysplasia in the adult mouse.
Multiple Sequence Variants in Hereditary Hemorrhagic Telangiectasia Cases. Illustration of Complexity in Molecular Diagnostic Interpretation.
Mutation analysis in Norwegian families with hereditary hemorrhagic telangiectasia: founder mutations in ACVRL1.
Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia.
Mutations in the ALK-1 gene and the phenotype of hereditary hemorrhagic telangiectasia in two large Danish families.
Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital.
Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease.
Non-invasive CT screening for pulmonary arteriovenous malformations in children with confirmed hereditary hemorrhagic telangiectasia: Results from two pediatric centers.
Novel mutation c.263A>G in the ACVRL1 gene in a Japanese patient with hereditary hemorrhagic telangiectasia 2.
Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype.
Novel protein interactions with endoglin and activin receptor-like kinase 1: potential role in vascular networks.
Novel Protein Interactions with Endoglin and Activin Receptor-like Kinase 1: Potential Role in Vascular Networks.
Overexpression of Activin Receptor-Like Kinase 1 in Endothelial Cells Suppresses Development of Arteriovenous Malformations in Mouse Models Of Hereditary Hemorrhagic Telangiectasia.
Pathogenesis of Brain Arteriovenous Malformations.
Pathogenesis of telangiectasia in scleroderma.
Patients with Hereditary Hemorrhagic Telangectasia (HHT) Exhibit a Deficit of Polymorphonuclear Cell and Monocyte Oxidative Burst and Phagocytosis: A Possible Correlation with Altered Adaptive Immune Responsiveness in HHT.
Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia.
Pulmonary arterial hypertension as the first manifestation in a patient with hereditary hemorrhagic telangiectasia.
Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology.
Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia.
Reduced mural cell coverage and impaired vessel integrity after angiogenic stimulation in the Alk1-deficient brain.
Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT).
Reduction of endoglin receptor impairs mononuclear cell-migration.
Regulation of ALK-1 signaling by the nuclear receptor LXRbeta.
Research on potential biomarkers in hereditary hemorrhagic telangiectasia.
Sequence variations of ACVRL1 play a critical role in hepatic vascular malformations in hereditary hemorrhagic telangiectasia.
Signaling by members of the TGF-beta family in vascular morphogenesis and disease.
SMAD4 Deficiency Leads to Development of Arteriovenous Malformations in Neonatal and Adult Mice.
Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1.
Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells.
The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2.
The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations.
The ALK-1/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?
Thoracic endografting in a patient with hereditary hemorrhagic telangiectasia presenting with a descending thoracic aneurysm.
Three novel mutations in the activin receptor-like kinase 1 (ALK-1) gene in hereditary hemorrhagic telangiectasia type 2 in Brazilian patients.
Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders.
Transforming growth factor-betas and vascular disorders.
Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain.
VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2.
[A rare cardiomegaly].
[Analysis of genetic mutation and modifier genes in pulmonary arterial hypertension]
[Clinical features and genetic screening of hereditary hemorrhagic telangiectasia].
[Gene Analysis of A Chinese Family with Hereditary Hemorrhagic Telangiectasia and its Curative Effect of Thalidomide].
[Gene diagnosis and treatment of hereditary hemorrhagic telangiectasia with epistaxis as its main symptom].
[Gene identification in a family of hereditary hemorrhagic telangiectasia].
[Hereditary hemorrhagic telangiectasia resulted from a nonsense mutation Arg479 Stop in the ALK-1 gene.]
[Liver involvement in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease). Report of one case and review of the literature.]
[Mutations of ACVRL1 gene in a pedigree with hereditary hemorrhagic telangiectasia]
Telangiectasis
12q13.12q13.13 microdeletion encompassing ACVRL1 and SCN8A genes: Clinical report of a new contiguous gene syndrome.
99mTc-MAA Pulmonary Scintigraphy in Hereditary Hemorrhagic Telangiectasia.
A Case of Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia Related to an ACVRL1 Mutation.
A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlinked to the known HHT genes, endoglin and ALK-1.
A mouse model of hereditary hemorrhagic telangiectasia generated by transmammary-delivered immunoblocking of BMP9 and BMP10.
A novel BMPR2 mutation in a patient with heritable pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia: A case report.
A novel ENG mutation causing impaired co-translational processing of endoglin associated with hereditary hemorrhagic telangiectasia.
A novel mutation in ALK-1 causes hereditary hemorrhagic telangiectasia type 2.
A Novel Variant in the ACVRL1 Gene in a Patient with Cirrhosis and Hereditary Hemorrhagic Telangiectasia
A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.
A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors.
A rare cause of fatal right ventricular cardiac decompensation.
Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs.
Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: potential roles for JNK and ERK.
Activin receptor-like kinase 1 is essential for placental vascular development in mice.
ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension.
ALK-1 mutations in liver transplanted patients with hereditary hemorrhagic telangiectasia.
Alk1 controls arterial endothelial cell migration in lumenized vessels.
ALK1 Signaling Inhibits Angiogenesis by Cooperating with the Notch Pathway.
Allelic dropout in the ENG gene, affecting the results of genetic testing in hereditary hemorrhagic telangiectasia.
Altered endothelial gene expression associated with hereditary haemorrhagic telangiectasia.
An Intron Mutation in the ACVRL1 May Be Associated with a Transcriptional Regulation Defect in a Chinese Family with Hereditary Hemorrhagic Telangiectasia.
Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2.
Arteriovenous malformation in the adult mouse brain resembling the human disease.
Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1.
Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system.
Bioinformatic analysis of pathogenic missense mutations of activin receptor like kinase 1 ectodomain.
BMP and activin type-II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.
BMP9 and BMP10: two close vascular quiescence partners that stand out.
BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II.
BMP9 Mutations Cause a Vascular-Anomaly Syndrome with Phenotypic Overlap with Hereditary Hemorrhagic Telangiectasia.
BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia.
Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors.
Bone morphogenetic protein signaling is required for RAD51-mediated maintenance of genome integrity in vascular endothelial cells.
Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression.
Casein kinase 2{beta} as a novel enhancer of activin-like receptor-1 signaling.
Characterization of pulmonary arteriovenous malformations in ACVRL1 versus ENG mutation carriers in hereditary hemorrhagic telangiectasia.
Clinical and molecular characterization of patients with hereditary hemorrhagic telangiectasia: Experience from an HHT Center of Excellence.
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.
Clinical features and mutations in the ENG, ACVRL1, and SMAD4 genes in Korean patients with hereditary hemorrhagic telangiectasia.
Clinical Features of Pulmonary Arterial Hypertension in Young People with an ALK1 Mutation and Hereditary Hemorrhagic Telangiectasia.
Cost comparison of genetic and clinical screening in families with hereditary hemorrhagic telangiectasia.
Curaçao diagnostic criteria for hereditary hemorrhagic telangiectasia is highly predictive of a pathogenic variant in ENG or ACVRL1 (HHT1 and HHT2).
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Detection of a significant association between mutations in the ACVRL1 gene and hepatic involvement in German patients with hereditary haemorrhagic telangiectasia.
DHPLC-based mutation analysis of ENG and ALK-1 genes in HHT Italian population.
Different forms of pulmonary hypertension in a family with clinical and genetic evidence for hereditary hemorrhagic teleangectasia type 2.
Directional next-generation RNA sequencing and examination of premature termination codon mutations in endoglin/hereditary haemorrhagic telangiectasia.
Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels.
Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients.
Effect of Transcriptional Regulator ID3 on Pulmonary Arterial Hypertension and Hereditary Hemorrhagic Telangiectasia.
Emerging role of bone morphogenetic proteins in angiogenesis.
Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH.
Endoglin in angiogenesis and vascular diseases.
Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction.
Endoplasmic Reticulum Associated Protein Degradation (ERAD) in the Pathology of Diseases Related to TGF? Signaling Pathway: Future Therapeutic Perspectives.
ENG mutational mosaicism in a family with hereditary hemorrhagic telangiectasia.
Evidence for the founder effect of a novel ACVRL1 splice-site mutation in Hungarian hereditary hemorrhagic telangiectasia families.
Functional analysis of mutations in the kinase domain of the TGF-beta receptor ALK1 reveals different mechanisms for induction of hereditary hemorrhagic telangiectasia.
Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations.
Functional and splicing defect analysis of 23 ACVRL1 mutations in a cohort of patients affected by Hereditary Hemorrhagic Telangiectasia.
Generation and genetic repair of 2 iPSC clones from a patient bearing a heterozygous c.1120del18 mutation in the ACVRL1 gene leading to Hereditary Hemorrhagic Telangiectasia (HHT) type 2.
Generation of mice with a conditional and reporter allele for Tmem100.
Genetic basis of pulmonary arterial hypertension: current understanding and future directions.
Genetic studies of pulmonary arterial hypertension.
Genetic variants of Adam17 differentially regulate TGF? signaling to modify vascular pathology in mice and humans.
Genetics of pulmonary hypertension: from bench to bedside.
Genome sequencing reveals a deep intronic splicing ACVRL1 mutation hotspot in Hereditary Haemorrhagic Telangiectasia.
Genotype-Phenotype Correlations in Children with HHT.
Global gene expression profiling of telangiectasial tissue from patients with hereditary hemorrhagic telangiectasia.
Heart failure and pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia type 2.
Hereditary haemorrhagic telangiectasia: A case report.
Hereditary hemorrhagic telangiectasia is caused by the Q490X mutation of the ACVRL1 gene in a large Arab family: support of homozygous lethality.
Hereditary hemorrhagic telangiectasia type 1 and 2 mutations in Finland.
Hereditary Hemorrhagic Telangiectasia: Breakpoint Characterization of a Novel Large Deletion in ACVRL1 Suggests the Causing Mechanism.
Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients.
Hereditary hemorrhagic telangiectasia: evidence for regional founder effects of ACVRL1 mutations in French and Italian patients.
Human retroviral gag- and gag-pol-like proteins interact with the transforming growth factor-beta receptor activin receptor-like kinase 1.
Identification of 13 new mutations in the ACVRL1 gene in a group of 52 unselected Italian patients affected by hereditary haemorrhagic telangiectasia.
Identification of a Novel ACVRL1 Gene Mutation (c.100T>A, p.Cys34Ser) in a Japanese Patient with Possible Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Disease).
Identifying common genetic variants by high-resolution melting.
Idiopathic pulmonary hypertension: what did we learn from genes?
Impact of genotype and mutation type on health-related quality of life in patients with hereditary hemorrhagic telangiectasia.
Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation.
Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex.
Intracranial hemorrhage in infants and children with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome).
Matrix Gla protein deficiency causes arteriovenous malformations in mice.
Minimal homozygous endothelial deletion of Eng with VEGF stimulation is sufficient to cause cerebrovascular dysplasia in the adult mouse.
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
Mosaic ACVRL1 and ENG mutations in hereditary haemorrhagic telangiectasia patients.
Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia.
Multiple Sequence Variants in Hereditary Hemorrhagic Telangiectasia Cases. Illustration of Complexity in Molecular Diagnostic Interpretation.
Mutation analysis in Norwegian families with hereditary hemorrhagic telangiectasia: founder mutations in ACVRL1.
Mutations in endoglin and in activin receptor-like kinase 1 among Danish patients with hereditary haemorrhagic telangiectasia.
Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia.
Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2.
Mutations in the ALK-1 gene and the phenotype of hereditary hemorrhagic telangiectasia in two large Danish families.
Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital.
Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease.
Non-invasive CT screening for pulmonary arteriovenous malformations in children with confirmed hereditary hemorrhagic telangiectasia: Results from two pediatric centers.
Novel human pathological mutations. Gene symbol: ACVRL1. Disease: haemorrhagic telangiectasia 2.
Novel mutation c.263A>G in the ACVRL1 gene in a Japanese patient with hereditary hemorrhagic telangiectasia 2.
Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype.
Novel protein interactions with endoglin and activin receptor-like kinase 1: potential role in vascular networks.
Novel Protein Interactions with Endoglin and Activin Receptor-like Kinase 1: Potential Role in Vascular Networks.
Overexpression of Activin Receptor-Like Kinase 1 in Endothelial Cells Suppresses Development of Arteriovenous Malformations in Mouse Models Of Hereditary Hemorrhagic Telangiectasia.
Pathogenesis of Brain Arteriovenous Malformations.
Pathogenesis of telangiectasia in scleroderma.
Patients with Hereditary Hemorrhagic Telangectasia (HHT) Exhibit a Deficit of Polymorphonuclear Cell and Monocyte Oxidative Burst and Phagocytosis: A Possible Correlation with Altered Adaptive Immune Responsiveness in HHT.
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.
Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia.
Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia.
Pulmonary arterial hypertension as the first manifestation in a patient with hereditary hemorrhagic telangiectasia.
Pulmonary arterio-venous malformations in a patient with a novel mutation in exon 10 of the ACVRL1 gene.
Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology.
Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia.
Reduced mural cell coverage and impaired vessel integrity after angiogenic stimulation in the Alk1-deficient brain.
Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT).
Reduction of endoglin receptor impairs mononuclear cell-migration.
Regulation of ALK-1 signaling by the nuclear receptor LXRbeta.
Research on potential biomarkers in hereditary hemorrhagic telangiectasia.
Sequence variations of ACVRL1 play a critical role in hepatic vascular malformations in hereditary hemorrhagic telangiectasia.
Signaling by members of the TGF-beta family in vascular morphogenesis and disease.
SMAD4 Deficiency Leads to Development of Arteriovenous Malformations in Neonatal and Adult Mice.
SMAD4 gene mutation increases the risk of aortic dilation in patients with hereditary haemorrhagic telangiectasia.
Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1.
Stroke after prolonged air travel associated with a pulmonary arteriovenous malformation.
Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells.
TGF-beta and BMPR-II pharmacology-implications for pulmonary vascular diseases.
TGF-beta receptor function in the endothelium.
The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2.
The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations.
The ALK-1/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?
Thoracic endografting in a patient with hereditary hemorrhagic telangiectasia presenting with a descending thoracic aneurysm.
Three novel mutations in the activin receptor-like kinase 1 (ALK-1) gene in hereditary hemorrhagic telangiectasia type 2 in Brazilian patients.
Transforming growth factor ?--at the centre of systemic sclerosis.
Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders.
Transforming growth factor-betas and vascular disorders.
Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain.
VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2.
[A rare cardiomegaly].
[Analysis of genetic mutation and modifier genes in pulmonary arterial hypertension]
[Analysis of molecular background of hereditary haemorrhagic telangiectasia--Rendu-Osler-Weber disease--preliminary results]
[Clinical features and genetic screening of hereditary hemorrhagic telangiectasia].
[Gene Analysis of A Chinese Family with Hereditary Hemorrhagic Telangiectasia and its Curative Effect of Thalidomide].
[Gene diagnosis and treatment of hereditary hemorrhagic telangiectasia with epistaxis as its main symptom].
[Gene identification in a family of hereditary hemorrhagic telangiectasia].
[Genetic diagnostics of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease)].
[Hereditary hemorrhagic telangiectasia resulted from a nonsense mutation Arg479 Stop in the ALK-1 gene.]
[Liver involvement in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease). Report of one case and review of the literature.]
[Mutations of ACVRL1 gene in a pedigree with hereditary hemorrhagic telangiectasia]
Testicular Neoplasms
Transforming growth factor-beta expression in human testicular neoplasms.
Thromboembolism
Pulmonary Hypertension in Hereditary Haemorrhagic Teleangiectasia.
Thrombosis
Activated platelets induce MLKL-driven neutrophil necroptosis and release of neutrophil extracellular traps in venous thrombosis.
Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension.
Gene mutations associated with thrombosis detected by whole-exome sequencing in paroxysmal nocturnal hemoglobinuria.
The necroptotic cell death pathway operates in megakaryocytes, but not in platelet synthesis.
Thyroid Carcinoma, Anaplastic
Inhibition of TGF-beta modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma.
Thyroid Neoplasms
Functional roles of the bone morphogenetic protein system in thyrotropin signaling in porcine thyroid cells.
Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein.
Toxoplasmosis
RIPK3 Facilitates Host Resistance to Oral Toxoplasma gondii Infection.
Tracheoesophageal Fistula
Anaplastic lymphoma of the cervical esophagus presenting as a tracheoesophageal fistula.
Triple Negative Breast Neoplasms
LEFTY1 Is a Dual-SMAD Inhibitor that Promotes Mammary Progenitor Growth and Tumorigenesis.
Tuberculosis
The Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth.
The structure of PknB in complex with mitoxantrone, an ATP-competitive inhibitor, suggests a mode of protein kinase regulation in mycobacteria.
ulp1 peptidase deficiency
Stromal Senp1 promotes mouse early folliculogenesis by regulating BMP4 expression.
Ureteral Obstruction
Arkadia-Smad7-mediated positive regulation of TGF-beta signaling in a rat model of tubulointerstitial fibrosis.
Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis.
Enhanced anti-fibrotic activity of plasmid DNA expressing small interference RNA for TGF-beta type II receptor for a mouse model of obstructive nephropathy by cationized gelatin prepared from different amine compounds.
EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-?/Smad and ROS signaling.
Transforming growth factor-beta receptor types I and II are expressed in renal tubules and are increased after chronic unilateral ureteral obstruction.
Urinary Bladder Neoplasms
Inhibition of TGF-beta receptor I by siRNA suppresses the motility and invasiveness of T24 bladder cancer cells via modulation of integrins and matrix metalloproteinase.
Transforming growth factor beta type I receptor acts as a potent tumor suppressor in rat bladder carcinoma.
Uterine Cervical Neoplasms
Correction: RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1? release, and efficient paracrine dendritic cell activation.
Effects of human papillomavirus type 16 E7 protein on the growth of cervical carcinoma cells and immuno-escape through the TGF-beta1 signaling pathway.
Low Necroptosis Process Predicts Poor Treatment Outcome of Human Papillomavirus Positive Cervical Cancers by Decreasing Tumor-Associated Macrophages M1 Polarization.
RIPK1 polymorphisms alter the susceptibility to cervical Cancer among the Uyghur population in China.
RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1? release, and efficient paracrine dendritic cell activation.
RIPK3-a predictive marker for personalized immunotherapy?
Vascular Calcification
Inflammation induces endothelial-to-mesenchymal transition and promotes vascular calcification through downregulation of BMPR2.
Vascular Diseases
A potential role for Insulin resistance in experimental pulmonary hypertension.
Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs.
Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: potential roles for JNK and ERK.
BMP9 and BMP10: two close vascular quiescence partners that stand out.
BMPR2 mutation is a potential predisposing genetic risk factor for congenital heart disease associated pulmonary vascular disease.
Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression.
Correction of Nonsense BMPR2 and SMAD9 Mutations by Ataluren in Pulmonary Arterial Hypertension.
Emerging role of bone morphogenetic proteins in angiogenesis.
Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH.
Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC.
Genetic variants of Adam17 differentially regulate TGF? signaling to modify vascular pathology in mice and humans.
Heterozygous null bone morphogenetic protein receptor type 2 mutations promote SRC kinase-dependent caveolar trafficking defects and endothelial dysfunction in pulmonary arterial hypertension.
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
Phenotypically-Silent Bone Morphogenetic Protein Receptor 2 (Bmpr2) Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing The Risk for Neointimal Transformation.
PPAR?-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension.
Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle.
TGF-beta and BMPR-II pharmacology-implications for pulmonary vascular diseases.
The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2.
The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells.
Vascular Malformations
A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).
Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system.
Genetic and molecular pathogenesis of hereditary hemorrhagic telangiectasia.
Genotype-Phenotype Correlations in Children with HHT.
Sequence variations of ACVRL1 play a critical role in hepatic vascular malformations in hereditary hemorrhagic telangiectasia.
Signaling by members of the TGF-beta family in vascular morphogenesis and disease.
Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1.
The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations.
Vascular System Injuries
Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension.
Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension.
Vascular injury triggers Krüppel-like factor 6 mobilization and cooperation with specificity protein 1 to promote endothelial activation through upregulation of the activin receptor-like kinase 1 gene.
Vein of Galen Malformations
An ACVRL1 gene mutation presenting as vein of Galen malformation at prenatal diagnosis.
Venous Thrombosis
Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension.
Ventilator-Induced Lung Injury
RIPK3 mediates pathogenesis of experimental ventilator-induced lung injury.
Ventricular Dysfunction, Right
Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency.
Virus Diseases
Necroptosis mediators RIPK3 and MLKL suppress intracellular Listeria replication independently of host cell killing.
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
RIPK3 interacts with MAVS to regulate type I IFN-mediated immunity to Influenza A virus infection.
RIPK3-driven cell death during virus infections.
RIPped for neuroinflammation.
[Pulmonary arterial hypertension]
[Pulmonary hypertension: from genetics to treatments]
Vitelliform Macular Dystrophy
Unveiling the interactions among BMPR-2, ALK-1 and 5-HTT genes in the pathophysiology of HAPE.
Vitiligo
RIPK1 regulates the survival of human melanocytes upon endoplasmic reticulum stress.
Vitreoretinopathy, Proliferative
[Expression of TGF-beta receptor II in periretinal membranes of proliferative vitreoretinopathy]
Vocal Cord Paralysis
Paediatric pulmonary hypertension caused by an ACVRL1 mutation presenting as Ortner syndrome.
West Nile Fever
RIPped for neuroinflammation.
Zika Virus Infection
The Nucleotide Sensor ZBP1 and Kinase RIPK3 Induce the Enzyme IRG1 to Promote an Antiviral Metabolic State in Neurons.